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ABSTRACT  
   
Vitamin B12, found only in animal products, is a water-soluble vitamin important 
for DNA methylation, purine and pyrimidine synthesis, and the myelination of nerves.  
Symptoms of vitamin B12 deficiency include anemia, gait disturbances, altered vibration 
proprioception, impaired vision, psychosis, depression, dementia-like illness, and 
ultimately death.  Because vegetarians and vegans consume fewer animal products in 
their diet than omnivores, they are inherently more at risk for developing these symptoms 
of vitamin B12 deficiency.  Thus, the purpose of this study is to examine the correlation 
between nervous system markers (balance, dexterity, and vibration sensitivity) and 
markers of vitamin B12 nutriture (serum B12 and serum holo-transcobalamin II) in a 
cross-sectional study (n=38).  In addition, the impact of daily oral vitamin B12 
supplementation on these markers in an 8-week randomized controlled trial was also 
examined (n=18).  The results of the cross-sectional study revealed a moderate 
correlation (R=-0.351, p=0.031) between serum B12 and left-hand functional dexterity.  
The results of the intervention study revealed no significant time*group interactions for 
markers of nervous system functions and biochemical values (after the removal of 
outliers).  In addition, the time*group interaction appeared to be larger for those 
individuals with a baseline serum B12 of less than 303 pmol/L.  These results suggest 
that vitamin B12 supplementation may have a more pronounced effect on those 
individuals who are in a state of vitamin B12 depletion (<303 pmol/L serum 
concentration).  In addition, the results also suggest that 8 weeks of oral supplementation 
is not a long enough period to create significant clinical change, and it is likely that 
improvements in neurological measures would require long-term supplementation. 
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CHAPTER 1 
INTRODUCTION 
Overview 
 Current research examining the prevalence of vitamin B12 (cobalamin) deficiency 
among vegetarians is extremely varied.  In a 2013 meta-analysis examining deficiency 
prevalence in 18 different studies, deficiency rates in vegetarians and vegans ranged from 
0-86.5% 1.  In studies where the mean or median age is between 22 and 29 years, the 
deficiency rate of lacto-ovo vegetarians ranges from 6% to 31% 2-4.  These rates of 
deficiency in the vegetarian population are higher than the national rate of 1.7% for 19-30 
year-olds 5 due to the lack of B12 in plant-based food 6.  Other populations at risk for B12 
deficiency include the elderly, bariatric surgery patients, those with a malabsorptive 
disease such as inflammatory bowel disease 7, and patients chronically taking antacids, 
Metformin (diabetes) 7, omeprazole (gastro esophageal reflux disease), and neomycin 
(antibiotic) 8.  Further, those with generally poor nutrition 9, including alcoholics and 
eating disorder patients, are at risk for vitamin B12 deficiency. 
This prevalence of deficiency is problematic because vitamin B12 is necessary for 
vital nervous system functions, including the synthesis of neurotransmitters and myelin 
sheaths. This myelination may be important for hand dexterity as the literature suggests 
possible connections between dexterity and myelination in adolescent-onset psychosis 
patients 10.   Dexterity is also linked to right cerebral white matter (e.g. bundles of 
myelinated axons in the brain 11 ) and primary motor cortex volume in healthy older 
adults 12.  Reduced hand functionality can decrease quality of life by negatively 
impacting daily activities, personal medical care, or various activities related to work 
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performance 13.  Subtle changes in hand dexterity may reveal subclinical deficiency 
which, if identified earlier, can aid in the prevention of serious complications of vitamin 
B12 deficiency such as impaired vision, personality changes 7, psychosis, depression, 
mania 8, and dementia-like illness 9. 
Despite a large amount of research regarding the impact of vitamin B12 
deficiency on markers of cognitive health, there is a gap in the knowledge base regarding 
the effect of vitamin B12 status on functional markers (such as dexterity, vibration 
sensitivity, and balance) of neuropathy in any population, including vegetarians.   
In micronutrient deficiency research, there is a common theme of examining the 
consequences of severe deficiency and largely ignoring vitamin depletion states, i.e. the 
low-end of the ‘normal’ spectrum.  Just as with many other vitamins, this matter persists 
in the realm of vitamin B12 research.  Irreversible neurological symptoms often appear in 
vitamin B12 deficiency 14, however, there is little research that has examined the very 
early and subtle signs of the onset of these symptoms.  Young adult vegetarians are an 
excellent model to examine the subtle onset of neurological consequences of B12 
deficiency, as they are more likely to have low or deficient vitamin B12 status than the 
average population.  Furthermore, the neurological consequences normally associated 
with aging will likely not be present in this young population (unless other underlying 
medical conditions are at play).  This research will examine, using an ‘at-risk’ population, 
whether subtle changes in dexterity are measurable and relate these changes to vitamin 
B12 status.   
In addition to understanding whether vitamin B12 status is associated with subtle 
changes in neurological function, it is not known whether vitamin B12 supplementation 
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improves neurological function in a population at risk for vitamin B12 deficiency, such as 
vegetarians.  An intervention study such as this will allow us to identify if subtle 
neurological consequences of vitamin B12 respond to supplementation in a vegetarian 
population.  According to the 1998 Dietary Reference Report, the onset of neurological 
symptoms in vitamin B12 deficiency is gradual 15.  However, according to this report, the 
RDA is based on the amount of B12 needed to prevent anemia and maintain “normal 
plasma levels” 15, rather than the prevention of subtle neurological symptoms (as research 
in this area was lacking when the report was created).  Thus the trend line used to create 
the RDA that describes the relationship between vitamin B12 consumption and the 
presence of anemia is based solely on hematological symptoms and does not take into 
account the neurological symptoms that often accompany vitamin B12 deficiency.  
Further, according to Briani et al., neurological symptoms often manifest prior to 
hematological symptoms 8.  If subtle neurological symptoms present in individuals with 
depleted or low (yet normal) nutriture states, then the quality of life can be negatively 
affected.  It is important to assess if markers of neurological decline positively respond to 
vitamin B12 supplementation, as this is an inexpensive and easy to access therapy.  In 
addition to improving quality of life, the timely identification and remedy of subtle 
neurological symptoms may reduce the financial consequences of vitamin B12 
deficiency, as consequences of neuropathy have the potential to contribute to decreased 
work productivity.  Furthermore, individuals with permanent neurological damage can 
accrue extensive medical expenses throughout their lifetime.  It is essential to explore and 
identify functional declines in populations at risk for B12 deficiency, as well as the 
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neurological consequences of and solutions to vitamin B12 deficiency, as cognitive and 
functional declines may have a large impact on quality of life. 
Purpose of Study 
The goal of this research is to understand the impact of deficient, depleted, and 
normal vitamin B12 status on previously unstudied neurological markers in healthy adult 
vegetarians and vegans.  In addition, we will also investigate a cause and effect 
relationship between vitamin B12 supplementation and improvements in dexterity, 
vibration sensitivity, and balance.  Collectively, the outcomes of this study will advance 
the field of nutrition and micronutrient metabolism by defining previously unstudied 
neurological consequences of vitamin B12 deficiency.  This study will lay the foundation 
for understanding the physiological consequences of subclinical vitamin B12 deficiency.  
The long-term goal of this research is to encourage the reexamination of the vitamin B12 
RDA guidelines.  
Research Aim and Hypothesis 
Our central hypothesis is that a vitamin B12 supplement intervention will be 
successful in improving vibration sensitivity, balance, and dexterity in young adult 
vegetarians.  This hypothesis has been determined based on evidence in the literature 
suggesting a possible link between vitamin B12, decreased myelination, and poor 
dexterity.  The rationale for our hypothesis is to discover previously unknown 
consequences of vitamin B12 deficiency in young adults, as well as to discover if these 
consequences are also subtly present in those with depleted or normal B12 nutriture.  The 
specific aims, which support the overall objective of the project, are as follows: 
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1. To examine correlations between vitamin B12 and dexterity (Purdue 
Pegboard Test, Functional Dexterity Test), vibration sensitivity (Physitemp 
Vibratron II), and balance (AMTI Accusway) in healthy, young vegetarians 
and vegans.  Due to the importance of vitamin B12 in nervous system function, 
we hypothesize that dexterity, vibration sensitivity, and balance will have a direct 
correlation with serum cobalamin concentrations. 
2. To identify changes in dexterity (Purdue Pegboard Test, Functional 
Dexterity Test), vibration sensitivity (Physitemp Vibratron II), and balance 
(AMTI Accusway) in a vitamin B12 supplement (500 mcg 1x day) 
intervention group compared to a placebo control group (vinegar pill 1x 
day).  Due to the impact of B12 nutriture on myelination, and the association 
between poor myelination and neuropathy, we hypothesize that dexterity, 
vibration sensitivity, and balance scores will improve in the intervention group, 
and no change will be detected in the control group. 
Definition of Terms 
Vegan: An individual who consumes no meat or fish, and consumes dairy or egg-
containing products less than once a week. 
Lacto-ovo Vegetarian:  An individual who consumes meat (i.e. fish, poultry, pork, beef, 
or any other animal product excluding dairy or eggs) less than once a week, but consumes 
eggs or dairy products (i.e. milk, yogurt, cheese) at least once a week 
Omnivore:  An individual who consumes meat or fish at least once a week. 
Dexterity: Fine motor skills of the hands 
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Vitamin B12: In this text, ‘vitamin B12’ and ‘B12’ will be used interchangeably.  Vitamin 
B12 is also known as cobalamin (Cbl).   
Limitations 
 There are 5 major limitations for this study: (1) the restricted population, (2) the 
lack of administering multiple types of vitamin B12 supplements, (3) the lack of a dose-
response component, (4) the limited time period in which the study will be conducted, (5) 
the lack of a crossover design, and (6) a small sample size. 
1. Vegetarians were chosen as the target population because they are more likely to be 
deficient than an individual from the general population.  However, this limits the 
external validity, as there may be other unknown lifestyle factors associated with 
vegetarianism that could affect the outcome variable. 
2. Although we will be testing the efficacy of an oral pill form vitamin B12 supplement 
on changes in dexterity and nerve conduction speed, we are not examining the effects 
of sublingual supplements, nasal sprays, or intramuscular injections.  Thus, the 
generalizability of the results of the study would not span to all forms of vitamin B12 
supplements. 
3. This study will only contain one intervention group, rather than multiple groups to 
test for a dose-response.  This also limits the generalizability of the results, as any 
changes (or lack of changes) in the outcome variable would only be attributed to the 
dosage used in this particular study. 
4. This study will be conducted over a period of 8 weeks with a single pre- and post-test.  
It is possible that a continued vitamin B12 supplement intervention would have 
additional effects after the specified 8-week period.  
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5. This study design is parallel in nature, rather than a crossover.  This is due to the 
storage of vitamin B12 in the liver for extensive periods of time.  Thus, a crossover 
design is often unfeasible for vitamin B12 supplement intervention studies.  If this 
study was conducted as a crossover study, the washout period would need to be at 
least 5 years in length. 
6. Although the ideal sample size for this study is 54 subjects, only 18 subjects 
completed the intervention portion of the study.  Thus, this study was underpowered. 
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CHAPTER 2 
REVIEW OF LITERATURE 
Introduction to Vitamin B12 
Vitamin B12 is a water soluble vitamin 16 that is synthesized by bacteria found in 
the intestinal tract of animals 17. B12 is important for some metabolic and neurologic 
functions in the body including cell division, DNA synthesis, folate metabolism, 
homocysteine metabolism, red blood formation, and myelination of nerve cells 14.  
Sources of B12 include animal products, such as milk, meat, eggs and fish 18.  B12 can 
also be found in fortified foods or plant products contaminated with B12 producing 
bacteria 17.  Vitamin B12 absorption into the bloodstream occurs due to a combination of 
high stomach acidity and the availability of intrinsic factor 14.  After absorption, 
metabolically active vitamin B12 is transported in the blood by transcobalamin II (TCII).  
Vitamin B12 can also be free in the blood, however, this form of B12 is not metabolically 
active.  
Because animal products are the major source of vitamin B12 in an individual’s 
diet, vegans and vegetarians are particularly at risk for developing a B12 deficiency.  In 
addition, the elderly are at a high risk for B12 deficiency due to a high incidence of 
achlorhydria, a condition that weakens stomach acid 14.  Symptoms of vitamin B12 
deficiency include changes to blood and bone marrow cells, as well as neurological and 
cognitive disorders 14.  Although symptoms of vitamin B12 deficiency are often severe, 
deficiency will often take several years to become symptomatic due to large stores of 
vitamin B12 in the body  14.  According to the National Institutes of Health (NIH), adults 
should consume at least 2.4 ug of vitamin B12 daily 19 (table 1).  However, the typical 
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daily consumption often exceeds this amount as the median daily consumption for 
females is 3.5 μg, and the median daily consumption for males is 5 μg 7. 
Table 1: Vitamin B12 Recommended Dietary Allowances (RDAs) by Age Group.  All 
values obtained from NIH 19. 
Population Vitamin B12 RDA (µg) 
0-6 months 0.4 
7-12 months 0.5 
1-3 years 0.9 
4-8 years 1.2 
9-13 years 1.8 
14-18 years 2.4 
Adults 2.4 
Pregnant women 2.6 
Breastfeeding women 2.8 
 
Absorption, Transport, Uptake, and Storage of Vitamin B12 
 The absorption and transport of vitamin B12 rely heavily on several proteins 
including intrinsic factor (IF), trans-cobalamin II (TCII), and hepatocorrin (HC).  The 
absorption process begins in the stomach, where gastric pepsin causes B12 to be released 
from proteins in food.   Next, vitamin B12 binds to hepatocorrins, which are proteins 
released in the saliva 20.  In addition, gastric acid in the stomach also stimulates the 
parietal cells of the stomach to release intrinsic factor, which has a strong affinity towards 
B12 and does not bind well with its analogues 21.  Intrinsic factor binds with vitamin B12 
in the small intestine, where the bond between hepatocorrins and B12 is hydrolyzed by 
pancreatic proteases 20.  The IF and vitamin B12 complex then binds to receptors on 
enterocytes in the distal ileum.  Next, the complex is absorbed and B12 is released into 
circulation bound to TCII.   In addition, about 1-3% of vitamin B12 can be absorbed into 
the enterocytes via passive diffusion 22. 
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Although the intercellular path of vitamin B12 within the enterocytes is still 
poorly understood 21, it is believed that there is a cellular, non-lysosomal vesicle that 
houses endogenously produced TCII, and provides the location for TCII-B12 complex 
formation.  The method for vitamin B12 entry into this vesicle, however, is unknown 23.  
In addition to this receptor-mediated enterocyte absorption, high doses of B12 can cause 
minimal absorption into circulation by diffusion 20.  After the IF-B12 compound is taken 
up by enterocyte cells via endocytosis, the complex is broken down within the lysosome.  
Intrinsic factor is then degraded.  Vitamin B12 is transferred to a separate vesicle, where 
it binds with TCII, and then is released into circulation via transcytosis 23.  It is essential 
for TCII to be continuously produced in the body, as its half-life is only about one hour 
24. 
 TCII is essential to vitamin B12 metabolism and carries 10-30% of vitamin B12 
in the body 21.  A small number of studies have found that the presence of the receptor for 
the TCII-B12 compound, TCb1R, is associated with the cell cycle.  This is believed to be 
due to the high need of vitamin B12 during DNA synthesis 21.  
 Circulating TCII-Cbl is distributed among body cells via circulation and is 
absorbed into body cells via receptor-mediated endocytosis 23.  Once in the cell, the TCII-
Cbl complex is taken up by a lysosome, where the TCII protein is degraded.  Free 
vitamin B12 is then released, where it will function in its coenzyme form 23. 
Vitamin B12 is also found free in the blood, as well as bound to hepatocorrins.  
Hepatocorrins, which released in the saliva, are also known in the literature as R-binder 
and TCI or TCIII 21.  Although no concrete function for these compounds has been 
defined by the literature, the fact that HCs do not have an affinity as precise as TCII and 
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IF for vitamin B12 suggests that hepatocorrins may prevent the assimilation of B12-like 
compounds into the vitamin B12 metabolic pathway.  In addition, these compounds may 
also serve to bind to free B12 and prevent the loss of free B12 from circulation 21.  In 
addition to this, vitamin B12 can also be reabsorbed during the excretory process (known 
as the enterohepatic pathway).  Significant amounts of vitamin B12 are released with 
bile, however a large amount binds with intrinsic factor in the small intestine to minimize 
loss in feces and urine.  Vitamin B12 released from sloughed intestinal cells is also 
reabsorbed in the same manner 7. 
Vitamin B12 is stored primarily in the liver, where up to 3 mg can be stored.  This 
amount is sufficient for up to 5 years of use at adequate plasma concentrations 20.  Thus, 
only individuals who fail to consume vitamin B12 for an extended period are likely to 
develop symptoms of deficiency. 
Transcobalamin II 
 Evidence of protein bound to circulating B12 was first discovered in the late 
1950s and early 1960s.  However, it wasn’t until 1972 that this substance, transcobalamin 
II, was first purified for the purpose of studying the chemical properties in detail 25.  
Although almost 55 years have passed, the metabolic pathways of transcobalamin II, the 
carrier of active vitamin B12, are still not fully documented in the literature 25,26.  Further, 
although some details are known about the particular genes that code for TCII, not much 
is known regarding the specific metabolic processes that regulate the synthesis of this 
essential molecule. 
The TCII gene (TCN2 26 ) is located on chromosome 22 25.  This gene does not 
contain a TATA promoter region, unlike the genes for intrinsic factor and hepatocorrin.  
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Genes without this factor are thought to produce protein at a relatively regular rate, as the 
TATA box is a genetic regulatory element 25.  However, some studies have demonstrated 
an increase of serum TCII in response to both oral 25 and intravenous 27 vitamin B12 
supplementation.  Some researchers believe this response to increased serum B12 is due 
to a 5’ flanking DNA sequence that acts as a regulatory element 25. 
Although many studies have explored the TCII synthesis ability of various tissues, 
there is yet another lack of consensus in the literature as to the predominant site of 
production.  Animal cell studies have yielded evidence of TCII production in the liver, 
peritoneal macrophages, and ileum.  However, an additional study examining 
hepatectomized dogs did not document a difference in TCII production, suggesting that 
the liver is not the main site for transcobalamin-II synthesis 25.  The human cell studies 
have yielded evidence of TCII production in liver tumors, fibroblasts, bone marrow cells, 
and umbilical cord vein endothelial cells 25.  Rothenberg and Quadros suggest venous 
endothelial cells as the predominant site for TCII synthesis.  Because vitamin B12 is 
delivered to tissues (where it is ultimately destroyed 23 ) via the circulatory system, 
arterial circulation will naturally have a higher concentration of TCII than venous 
circulation.  Thus, Rothenberg and Quadros proposed that this insufficient concentration 
of TCII stimulates production from venous endothelial cells.  Due to the large surface 
area of the venous endothelium, these cells are more likely to efficiently replenish TCII 
25.  However, this study was conducted using human umbilical cord vein cells, which 
may behave differently from other venous endothelial cells. 
Although research has largely ignored the synthesis and regulation of TCII, much 
recent research has been devoted to TCII receptor regulation.  TCII receptors are present 
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in various tissues such as the heart, lungs, small intestine, spleen, liver, and kidneys 25.  
As vitamin B12 is an important substance for DNA synthesis and DNA methylation, B12 
uptake occurs in all types of cells 23.  The TCII-B12 complex binds to the TCII receptor 
in a biphasic reaction that is temperature and pH dependent, and requires divalent cations 
such as Ca2+ or Mg2+ 25.  The TCII-Cbl complex moves into the cell via receptor-
mediated endocytosis, after which the TCII receptor can be recycled 25. 
Metabolism of Vitamin B12 
 The four biologically significant cobalamins are hydroxycobalamin, 
adenosylcobalamin, methylcobalamin, and cyanocobalamin.  Most vitamin B12 in food 
comes in the form of hydroxycobalamin, whereas most B12 in supplements comes in the 
form of cyanocobalamin.  The remaining two vitamin B12 vitamers are 
adenosylcobalamin and methylcobalamin, which are the metabolically active forms of 
vitamin B12 7. The metabolism of vitamin B12 can be divided into two separate 
categories based on the location of activity: cytoplasm or mitochondria.  Once vitamin 
B12 is absorbed into the cell, it is converted to either adenosylcobalamin or 
methylcobalamin, which act as coenzymes for two essential metabolic processes in the 
body 21. 
Vitamin B12 metabolism in the cytoplasm utilizes methylcobalamin, one of the 
active vitamin B12 vitamers, as the cofactor for the methionine synthase enzyme.  This 
process, also known as the methylation cycle, serves numerous metabolic functions 20.  
The methionine synthase enzyme serves to convert homocysteine to methionine.  
Methionine is then converted (using ATP) to S-adenosyl methionine, which acts as a 
methyl donor for DNA methylation.  This process of DNA methylation is important in 
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the epigenetic modification of gene expression 20.  During this methyl donation, S-
adenosyl methionine becomes S-adenosyl homocysteine, which is then converted back to 
homocysteine (Hcy). 
This methionine synthase enzyme action also plays a major role in the folate 
cycle.  The conversion of homocysteine to methionine requires a methyl donor, 5-CH3-
tetrahydrofolate.  During this methyl donation, 5-CH3-tetrahydrofolate becomes 
tetrahydrofolate (THF) 20.  Thus, folate is the methyl donor for this portion of the cycle.  
The production of THF is necessary for purine synthesis and the next step in the folate 
cycle (methyleneTHF) is essential for pyrimidine synthesis 20.  These purines and 
pyrimidine nucleotides are the main components of DNA, RNA, and nucleoside 
triphosphates (such as ATP) 20.  Thus, not only is methylcobalamin essential for proper 
DNA and RNA synthesis, but it is also essential for controlling the expression of this 
genetic material. 
Vitamin B12 metabolism in the mitochondria utilizes adenosylcobalamin, the 
second active vitamin B12 vitamer, as the cofactor for methyl malonyl-CoA mutase 
enzyme.  This vitamin B12 dependent enzyme is essential for the breakdown of 
propionyl-CoA, a three carbon compound which results from the breakdown of odd-
numbered chain fatty acids during β-oxidation in the mitochondria 20.  This propionyl-
CoA is converted to methyl malonyl-CoA, which is then converted to succinyl-CoA by 
methylmalonyl-CoA mutase 20.  The resulting succinyl-CoA can then enter into the TCA 
cycle for energy production.  A lack of B12 thus results in the inhibition of the methyl 
malonyl-CoA mutase enzyme and buildup of methyl malonyl-CoA (MMA CoA) and 
methylmalonic acid (MMA).  Further, because the rate of this enzymatic process is 
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regulated by the concentration of products produced after the succinyl-CoA metabolic 
step, a buildup of MMA CoA inhibits the transfer of long-chain fatty acids into the 
mitochondria.  Thus, this leads to an abnormal accumulation of these fatty acids in the 
cytoplasm 20. 
Applications in Heart Disease 
Vegetarian diets have been found to improve several biochemical markers 
including as C-reactive protein, oxidative stress, blood glucose, and lipid profiles; 
increases in all of which are associated with an increased risk for heart disease 28.  In 
addition, vegetarian diets are also protective against arterial plaque formation, associated 
with lower blood pressure (both systolic and diastolic), and associated with a lower 
prevalence of overweight and obese individuals 28.  Contrary to what is expected, 
however, these lowered risk factors do not always translate to a decreased prevalence of 
heart disease in vegetarians and vegans. 
Surprisingly, some vegetarian and vegan populations examined in the literature 
displayed an increased prevalence of heart disease when compared to omnivores 28.  For 
example, a 2013 paper reporting and reviewing preliminary results from the EPIC-Oxford 
study (n=55,041) found a standardized mortality ratio (SMR) for circulatory disease to be 
38% in non-vegetarians, but 40% in vegetarians 29.  In addition, the SMR for 
cerebrovascular disease was found to be 41% in non-vegetarians and 52% in vegetarians.  
However, this study did find a higher all cause mortality in non-vegetarians (SMR = 
39%) than in vegetarians (SMR = 40%) 29.  The participants in this study were 
predominantly female (78% of the non-vegetarians and 75% of the vegetarians).  The 
median age for the non-vegetarians in this study was 47 years old, while the median age 
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for the vegetarians was 36 years old at baseline 29.   The Adventist Health Study 2, which 
examined mortality in vegetarians and vegans in 73,308 participants, also found an 
increased risk for death due to vascular disease in certain vegetarian or vegan cohorts 30.  
The hazard ratio of death due to ischemic heart disease was 1.39 in female vegans, and 
1.09 in female semi-vegetarians compared to the reference population of female non-
vegetarians (hazard ratio = 1).  The hazard ratio of death due to cardiovascular disease 
was 1.18 in female vegans compared to non-vegetarians 30.  None of the hazard ratios for 
vascular disease were higher than that of the reference population in male vegetarians or 
vegans.  However, in the overall populations, the hazard ratio of death due to vascular 
conditions is lower than that of the non-vegetarian reference population 30.  In this study, 
the mean age of the dietary groups ranged from 55.9 years to 58.8 years old.  In addition, 
the prevalence of females ranged from 63.8% to 69.7% of the sample size 30.  Although 
the risk of some types of cardiovascular disease may be higher in certain subsets of the 
vegetarian population, the overall risk of circulatory health problems in the vegetarian 
and vegan populations tend to be lower than the omnivorous population 28-30. 
Pawlak suggests, however, that vegetarian diets are not as protective against 
vascular disease as previously thought 28.  The reason for this inconsistency between 
theory and observation is likely due to high serum homocysteine concentrations 
commonly present in vegetarians and vegans.  A recent meta-analysis of 21 studies 
examining hyperhomocysteinemia in in vegetarian adults found an average homocysteine 
concentration above 15 μmol/L (the most conservative definition of 
hyperhomocysteinemia) in vegetarians or vegans in 11 of the studies 28.  There is ample 
evidence in the literature that documents an association between increased serum 
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concentrations of homocysteine and an increased risk of heart disease 4,28,31-33, 
particularly venous thrombosis, coronary heart disease, stroke 32, and extracranial carotid 
artery stenosis 28. 
Homocysteine is thought to contribute to this increased risk of heart disease 
primarily by atherogenesis.  Acute hyperhomocysteinemia is associated with decreased 
nitrous oxide synthesis, increased LDL oxidation, and endothelial inflammation, and 
increased foam cell formation; while chronic hyperhomocysteinemia is associated with 
decreased superoxide dismutase activity, aortic calcification  28.  All of these metabolic 
changes contribute to the development of cardiovascular disease.  Vitamin B12 
deficiency, independent of hyperhomocystenemia, can contribute to circulatory problems 
via B12 induced macrocytosis (abnormally large blood cells), and have been shown to 
increase the risk for fatal coronary disease, fatal and nonfatal myocardial infarction, 
stroke, and symptomatic heart failure 28.  Thus, vitamin B12 deficiency contributes to an 
increased risk for heart disease using several metabolic processes. 
Homocysteine, or tHCY, is a metabolite in the methylation cycle of vitamin B12 
metabolism.  As mentioned above, tHCY is converted to methionine by methionine 
synthase, a vitamin B12 dependent enzyme 20.  When vitamin B12 serum concentrations 
are low, as is common in vegetarians, methionine synthase does not function at full 
capacity.  Consequentially, homocysteine concentrations tend to be higher in populations 
at an increased risk for vitamin B12 deficiency, such as vegetarians and vegans.  Using 
the data from the 3rd NHANES study, hyperhomocysteinemia (high homocysteine 
concentration) is defined as ≥11.4 μmol/L for men and ≥10.4 μmol/L for women 28.  
Suboptimal methionine synthase enzyme activity can also be due to inadequate serum 
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folate, as folate acts as a methyl group donor in the methionine synthase reaction.  Thus, 
folate deficiencies can also cause increased serum homocysteine concentrations.  
However, hyperhomocysteinemia is more likely to be caused by low vitamin B12 than 
low folate.  In one study, 0.3% of the risk for high tHCY was credited to low folate, 
whereas 29.7% was attributed to low serum B12 and 36.4% to inadequate TCII 28. 
Among the general population, hyperhomocysteinemia typically ranges in 
prevalence from 9-15%, with higher rates in female adolescents and elderly women 28.  
However, similar to the research examining the rates of vitamin B12 deficiency in 
vegetarian and vegan populations, a 2015 meta-analysis found prevalence rates of 
hyperhomocysteinemia to be between 12 and 78% of the vegetarian and vegan 
populations 28.  Results from Pawlak’s meta-analysis showed, however, that 13 of the 20 
studies examined documented a hyperhomocysteinemia prevalence above 50% in 
vegetarian and/or vegan populations 28. 
According to the Hordaland Homocysteine Study, increased serum homocysteine 
concentrations are associated with a variety of other demographic characteristics in 
addition to the diet.  These include the male gender, age, physical inactivity, the number 
of cigarettes smoked per day, coffee intake (cups/day), high blood pressure, and high 
cholesterol (although these last two associations were weak) 32.  Refsum et al. also found 
that three of these factors combined had a much more significant effect on tHCY 
concentration than did one factor alone.  However, investigators also noted that lifestyle 
changes, such as smoking cessation and increased folate intake, can reduce tHCY 
concentrations 32.  Thus, although high homocysteine concentrations are a consequence 
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of inadequate vitamin B12 consumption, these elevated values can also be due to other 
unrelated factors. 
Few studies have examined the impact of utilizing B vitamin supplementation to 
decrease serum homocysteine concentrations, with the ultimate goal of reducing the risk 
of heart disease.  However, many studies have been conducted to examine the 
effectiveness of vitamin B12 supplementation to simply reduce tHCY levels 32.  More 
specifically, B vitamin supplementation is a commonly used treatment for 
homocystinuria (excessive serum tHCY) due to cystathionine β-synthase deficiency, 
which will eventually lead to death if untreated 32.  Thus, although high tHCY levels have 
the potential to diminish protective effects of a vegetarian diet against heart disease, it is 
possible that supplementing the diet with vitamin B12 and folate (if inadequate) may 
mitigate any negative effects that homocysteine concentrations have on vascular disease 
risk in vegetarians and vegans.  
Folate and Vitamin B12 Interaction 
Because the major cause of megaloblastic anemia is a decrease in methyleneTHF, 
folate deficiency, in addition to vitamin B12 deficiency, can also manifest in 
megaloblastic anemia.  Thus, unless serum concentrations of folate and vitamin B12 are 
examined, it is impossible to determine which vitamin deficiency is the cause of 
megaloblastic anemia 8.  This is problematic because, as early case reports demonstrate, 
B12 deficiency was often mistaken for folate deficiency and treated only with folate.  As 
a result, there is alleviation of the anemia-like symptoms, but no alleviation of 
neurological symptoms 34.  Thus, folate supplementation is known to affect the symptoms 
related to a vitamin B12 deficiency.  However, there is a large gap in the literature 
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documenting the consequences of folate supplementation in B12 deficient individuals (in 
both human and animal subjects) 34.  Thus, how folate impacts the presentation of vitamin 
B12 deficiency symptoms is still debated in the literature.  It is accepted that 
supplemental folate (folic acid) masks macrocytic anemia symptoms, but it is largely 
debated whether high supplemental folate exacerbates neurological symptoms in vitamin 
B12 deficiency 35,36.   In this masking effect, high consumption of folic acid can change 
the distribution of cellular folate.  This leads to the un-methylated folic acid bypassing 
the need for the conversion of methyltetrahydrofolate, and continue the process for DNA 
synthesis 34. 
Although the exact mechanism for heightened neurological degradation in 
vitamin B12 deficient but folate surplus individuals has only begun to be revealed in the 
literature; there is an increasing amount of evidence that high folate levels in individuals 
with low vitamin B12 status are associated with cognitive impairment 34.   This 
association, however, is not present in individuals with normal vitamin B12 nutriture.  In 
fact, in individuals with normal vitamin B12 nutriture, a high plasma folate concentration 
was found to have a protective effect on cognition 34.  Selhub et al. suggest the reason for 
an increased neurological degradation in the presence of high folate is worsening 
enzymatic function of B12 in vitamin B12 deficient individuals 34.  This study examined 
NHANES data on folate, vitamin B12, MMA, and total homocysteine (tHcy) in 
otherwise healthy adults 20 years and older.  The presence of high plasma folate in this 
study was attributed to vitamin supplements and folate fortification of food34.  Results 
revealed that, in individuals with low vitamin B12, there was a ‘U’ shaped curve for tHcy 
and MMA data.  Data showed an intermediary range where tHcy and MMA values were 
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normal, but values increased in the presence of both low and high folate 34.  These results 
were not entirely expected as folate only directly interacts with the portion of vitamin 
B12 metabolism (methylcobalamin) that results in elevated tHcy levels.  Thus, although 
Selhub et al. states that high folate concentrations must also affect the activity of 
adenosylcobalamin, they also acknowledge that it is difficult to imagine how this occurs.  
Selhub et al. suggests two possibilities for the theory that high folate in vitamin 
B12 deficient individuals exacerbates neurological consequences.  One hypothesis of 
how folate may interact with the methionine synthase (MS) and methyl-malonyl CoA 
mutase (mutase) enzymes, which Selhub acknowledges is unlikely, is an interaction with 
the reduction of cob(II)alamin to cob(I)alamin.  This process occurs in both metabolic 
processes of vitamin B12 metabolism, but is drastically different in each part of the cell 
34.  A second hypothesis Selhub suggests that folate may interact with both the MS and 
mutase enzymes is in the same way that nitrous oxide inhibits both processes.  Although 
it is not known exactly how nitrous oxide affects the mutase enzyme, people exposed to 
high amounts of inhaled nitrous oxide have increased tHcy and MMA 34.  As evidenced 
by the decreased activity of adenosylcobalamin when exposed to nitrous oxide, the 
activity of adenosylcobalamin and methylcobalamin may impact each other in some way 
34.  This second hypothesis, according to Selhub et al., is more likely.  Thus, the 
exacerbation of clinical symptoms of vitamin B12 deficiency in the presence of high 
plasma folate is thought to be due to an interruption of normal metabolic vitamin B12 
functioning in the mitochondria, similar to nitrous oxide toxicity, resulting in higher 
concentrations of tHcy and MMA 34.  Due to this interaction between folate and vitamin 
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B12, it is essential to measure and possibly control for plasma folate concentrations when 
examining vitamin B12 in research studies. 
Biochemical Assessment Methods 
Interest in the medical benefits of vitamin B12 began in 1926, when George 
Minot and William Murphy discovered that pernicious anemia, a complication of B12 
deficiency, could be treated by feeding inflicted patients a diet high in liver 14.  Since 
then, a number of assessment tools have been developed to measure an individual’s 
vitamin B12 status and assess risk for deficiency.  Three available measurement tools to 
assess vitamin B12 status are total serum B12, serum TCII, and urinary methylmalonic 
acid (MMA).  Serum TCII is the earliest indicator of B12 stage 1 negative balance (<40 
pg/mL), where a normal TCII concentration is >50 pg/mL 6.  Serum TCII is an excellent 
indicator of B12 status because it only transports metabolically active forms of B12.  
Total serum B12 is a late stage indicator of B12 deficiency, where normal serum B12 is 
300-300 pg/mL 6.  This is because an individual can be deficient in metabolically active 
B12, yet still have significant quantities of free B12 in the blood.  Urinary MMA, which 
is inversely associated with B12 intake, is considered the best marker of the extent of low 
B12 status, once deficiency has been reached.  Vitamin B12 deficiency is indicated by a 
urinary MMA concentration >271 nmol/L  1. 
Because each of the available B12 assessment tests appear to function best in 
individuals with different B12 concentrations, there is no consensus in the field of 
medicine as to which test should be used as the universal biomarker for B12 deficiency 
14.  This dilemma is particularly complicated by the wide range of B12 concentrations 
that different diet categories (vegan, vegetarian, and omnivore) can produce.  In addition, 
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although TCII appears to be the earliest indicator of vitamin B12 deficiency; there is no 
clear consensus in the literature as to the clinical implications of low TCII 24.  Further, as 
TCII needs to be continuously produced due to its short half-life, this functional marker 
may not be the best indicator of long term B12 status.  The problem with short half-life in 
TCII is similar to that of 1,25-dihydroxyvitamin D, which has a half life of 4-15 hours 37.  
According to the Institute of Medicine, this active form of vitamin D is not the ideal 
method to measure vitamin D status due to the strict regulation of this compound 38.  It is 
possible that a similar mechanism may be occurring with TCII.  More research is needed 
regarding the regulation of TCII and the impact of its short half-life on its value as an 
indicator of vitamin B12 nutriture. 
Vitamin B12 Deficiency: Populations at Risk 
Current research examining the rate of vitamin B12 (cobalamin) deficiency 
among vegetarians is extremely varied, citing deficiency rates ranging from 0-86.5% 1.  
In studies where the mean or median age is between 22 and 29 years, the deficiency rate 
of lacto-ovo vegetarians ranges from 6% to 31% 2-4.  These rates of deficiency in the 
vegetarian population are higher than the national rate of 1.7% for 19-30 year-olds 5 due 
to the lack of B12 in plant-based food 6.   
Table 2. Amount (µg) of vitamin B12 in common food sources.  Nutrient information 
obtained from the USDA SuperTracker™ website 39. 
Food Source µg of B12 Percent of Adult RDA 
Beef liver (braised, 3oz) 58.8 2450% 
Clams (1 medium, raw) 7.2 299% 
Hamburger patty 
(¼ lb., less than 80% lean) 
2.2 92% 
Cheerios® cereal (1 cup) 1.9 78% 
Milk, reduced fat (2%, 1 cup) 1.3 54% 
Cheddar cheese (¼ cup shredded) 0.2 10% 
Tofu (1 cup, ½” cubes) 0.0 0% 
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Other populations at risk for B12 deficiency include the elderly, bariactric surgery 
patients, those with a malabsorptive disease such as inflammatory bowel disease 7, and 
patients taking chronically taking antacids, Metformin (diabetes) 7, omeprazole (gastro 
esophageal reflux disease), and neomycin (antibiotic) 8.  Further, as those with generally 
poor nutrition are at risk 9, alcoholics and eating disorder patients may also develop 
vitamin B12 deficiency.  Thus, as vegetarians and older adults are the two largest 
population groups without inherent medical conditions which are likely to be deficient in 
vitamin B12, they are ideal groups to conduct research regarding the consequences of 
vitamin B12 deficiency. 
Vitamin B12 Deficiency in Vegetarians and Vegans 
 Vegetarians and vegans are more likely to become deficiency in vitamin B12 than 
an omnivore population because vitamin B12 is only found in animal sources, which are 
decreased or absent in vegetarian and vegan diets.  Although there are several studies 
examining the vitamin B12 status of vegetarians 40-43, there are no large studies 
examining the prevalence of vitamin B12 deficiency in young adult vegetarians and 
vegans.  Out of eighteen studies included in a 2013 review examining vitamin B12 
deficiency, none focused on a young adult population 40.  The results of this review cited 
deficiency prevalence ranging from 11% to 86% 40.  The age, diet duration and 
assessment criteria used in this study varied widely, depicting the need for a large 
population based study with clearly defined population parameters and assessment 
criteria.  Most research in this area is focused on deficiency rates in older adults, children, 
and pregnant women.  According to a recent review by Pawlak et al., the individuals 
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within this diet category who are most at risk for deficiency were those who did not 
consume supplements or fortified foods 1.  In addition, those who were considered ‘strict’ 
vegans were more likely to be deficient than ‘moderate’ vegans 1.   Thus, due to the 
increased risk for deficiency, along with a lack of decreases in dexterity associated with 
aging, young adult vegetarians are an ideal population to examine the effects of vitamin 
B12 deficiency on dexterity. 
 In a 2009 review published in the American Journal of Clinical Nutrition, 
Elmadfa and Singer examined vitamin B12 nutriture on a global level by analyzing 16 
studies.  Results from this review identified two studies from Germany (n=186, n=131) 
and one study from India (n=204) where the mean serum concentration of vitamin B12 
was less than 148 pmol/L in vegetarians or vegans 42.  In all of the 16 studies cited in this 
review, the stricter diet types (i.e. vegans, vegetarians) had lower serum B12 than the less 
strict diet types (i.e. omnivores), with the exception of one study that only examined 
vitamin B12 nutriture in one diet type (vegetarians) 42. 
A second study resulting from the EPIC-Oxford cohort study examining vitamin 
B12 nutriture in 689 men found that 52% of vegans (n=121) and 7% of vegetarians 
(n=16) were identified as deficient.  In this sample, however, deficiency was defined as 
serum B12 less than 118 pmol/L43.   Mean age for this study ranged from 42.8 years to 
52.8 years old (ages were reported for diet groups only, not total the total sample).  
However, the vegan group had a significantly larger amount of young adults ranging 
from 20-39 years of age.  Thus, it is likely that the deficiency prevalence would be 
slightly higher if 148 pmol/L were used to define deficiency.  As this study only 
examined a male sample, these results cannot be extrapolated to a female population. 
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A third study examining vitamin B12 nutriture also found a higher prevalence of 
deficiency in vegetarians (n=53) and vegans (n=12), compared to omnivores (n=79) 44.  
This study used the following vitamin B12 deficiency cut offs established by Herbert et 
al.: normal (MMA≤ 271 nmol/L and TCII≥ 35 pmol/L) stage I or II deficiency (MMA≤ 
271 nmol/L and TCII<35 pmol/L), and stage III deficiency (MMA > 271 nmol/L and 
TCII < 35 pmol/L) 6.  The results of the study by Hermann et al. showed that 83% of 
vegans, 60% of vegetarians, and 3% of omnivores fell into the stage II deficiency 
category.  Although there is a markedly higher prevalence of deficiency in the vegan 
sample from this study, the number of vegan subjects in this study is small (n=12) 44. 
Vitamin B12 deficiency can present early on in life, with evidence of several 
cases of infant vitamin B12 deficiency in the literature 45.  Honzik et al. found that severe 
vitamin B12 deficiency in infants is predominantly influenced by low maternal B12 
nutriture.  Further, this study also showed that infants can still be at risk for deficiency, 
even if their mother’s serum B12 concentration is considered normal.  This is particularly 
the case when a mother’s serum B12 concentration is on the low end of the ‘normal’ 
spectrum, as well as when a mother’s breast milk contains inadequate B12 45.  The 
majority of mothers in this study were not vegetarians, but rather had inadequate 
intestinal absorption of vitamin B12 45.  Nonetheless, infants with vegetarian or vegan 
mother also tend to develop vitamin B12 deficiency early in life if maternal vitamin B12 
nutriture is low 46.  In a study examining 27 infants with vitamin B12 deficiency 
symptoms in India who were exclusively breast-fed and all were born to vegetarian 
mothers, the authors found that 12 of these infants have low serum B12 46.  Out of the 
other 15 infants, six did not have their serum B12 measured, and nine had normal serum 
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B12.  However, seven of these nine infants had received supplemental vitamin B12 prior 
to enrolling in the study 46.  Twenty-two of the infants displaying symptoms of vitamin 
B12 deficiency were treated with supplemental B12.  Although one subject was lost to 
follow-up, twenty of the infants treated with supplemental serum B12 had a dramatic 
reduction of symptoms 46.  Thus, although the symptoms of deficiency in an infantile 
population can be severe (such as failure to thrive, weaning difficulties, and 
developmental regression), supplementation is an important treatment tool and should be 
evaluated for use in at-risk populations prior to the diagnosis of maternal or infant 
deficiency. 
Vitamin B12 Deficiency: Symptoms and Consequences 
Symptoms of vitamin B12 deficiency generally fall into two categories: 
hematological and neurological.  Hematological symptoms are thought to stem from the 
methylation cycle, where methylcobalamin acts as a coenzyme in the folate cycle in the 
conversion of homocysteine to methionine.  Decreased vitamin B12 availability causes a 
decrease in methyleneTHF which results in a decreased conversion of deocyuridylate to 
thymidylate, leading to an accumulation of uracil.  This excess uracil competes with 
thymine for incorporation into DNA coding for neucleoproteins, which ultimately leads 
to megaloblastic anemia 7.  The hematological presentation of vitamin B12 deficiency 
can include an increase in mean corpuscular volume (MCV), hypersegmentation of 
neutrophils, and macroovalocytes 8.  Ultimately, severe anemia can lead to symptoms 
such as fatigue, ankle edema, nocturia, dizziness, and orthostatic hypotension 8.  In 
addition, recent research has documented risk for decreased bone mineral density and 
osteoporosis in individuals with low vitamin B12 nutriture 47.  This prevalence of 
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deficiency is problematic because vitamin B12 is necessary for vital nervous system 
functions, including the synthesis of neurotransmitters and myelin sheaths. This 
myelination may be important for dexterity as the literature suggests possible connections 
between dexterity and myelination in adolescent-onset psychosis patients 10, dexterity and 
right cerebral white matter volume (white matter is bundles of myelinated axons in the 
brain 11 ), and primary motor cortex volume in healthy older adults 12.   
DNA Methylation 
 The lack of methylation capabilities due to the decreased functioning of 
methionine synthase in vitamin B12 deficiency and depletion can have substantial 
epigenetic consequences.  Studies examining the effect of decreased vitamin B12 
availability in utero, in both sheep and human models, have shown that the methylation 
patterns established during this time continue to affect the DNA methylation of said 
individual for the remainder of their life 20.  According to the “developmental origins of 
health and disease” hypothesis, this methylation is particularly important because 
prenatal DNA methylation can contribute to epigenetic regulation of disease risk later in 
life 48.  In spite of a large amount of research on DNA methylation, epigenetic regulation 
is still a relatively young field.  Further, the extent to which B vitamins affect DNA 
methylation in adulthood is largely unknown 48.  In one recently conducted study (2015), 
investigators discovered an increased in DNA methylation in adults 65-75 years old after 
a two-year vitamin B12 supplement intervention.  Some genes which displayed changes 
in methylation upon vitamin B12 supplementation include a tumor suppressor gene 
(DIRAS3), a gene associated with cancer metastasis (NODAL), and other genes 
association with embryonic development 48. 
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Nervous System Interactions 
 It is thought that one of the main reasons for the neurologic consequences in 
vitamin B12 deficiency is the interruption in myelination due to a buildup of methyl-
malonic acid 20.  In addition, the methylation cycle is also thought to play a role due to a 
decrease in S-adenosyl methionine (SAM), which leads to a decrease in the methylation 
of proteins necessary for myelination as well as a decrease in white matter vacuolization 
20.  Impaired DNA methylation, stemming from a decrease in methionine synthase 
activity, is also believed to affect the nervous system through a decrease in myelination 
and oligodendrocyte growth 7.  As myelin sheath is composed largely of lipids (80%), 
disturbances in fat metabolism can be especially problematic 20. 
One of the more severe neurologic consequences of vitamin B12 deficiency are 
neural tube defects (NTDs).  As the neural tube becomes fully closed by 28 days of 
gestation 20, ensuring adequate vitamin B12 nutriture for all women of reproductive age is 
essential to further decrease rates of neural tube defects at birth.  Although it is 
commonly accepted that folate depletion drastically increases the risk for NTDs, Bell and 
Oakley estimated that only 75% of spina bifida and anencephaly can be prevented by 
folic acid fortification 49.  Inadequate maternal vitamin B12 nutriture possibly contributes 
to a large part of the remaining cases of NTDs, as a 2007 case-control study examining 
NTDs in 89 Canadian women (with 422 controls) found a nearly tripled risk of NTDs in 
the presence of low maternal B12 50.  Further, Ray et al. suggests 34% of NTDs in 
Canada may be due to inadequate vitamin B12 50.  A recent meta-analysis examining nine 
studies with cases of NTDs (n=567) and controls (n=1566) found the risk (OR) of 
developing NTDs was 2.31 if maternal B12 nutriture was inadequate 51.  When further 
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examining this risk, investigators discovered an elevated risk for NTDs due to low 
maternal B12 in developing countries (OR=5.07) than in developed countries (OR= 2.10) 
51.  It is important to note that the authors suggest the strong possibility of publication 
bias in this area 51, meaning that many studies which discovered no association between 
maternal B12 nutriture and risk of NTDs were likely not published. 
Clinically, however, the most recognized symptom of vitamin B12 deficiency is 
myelopathy, referred to by physicians as subacute combined degeneration.  Early 
decreases in function associated with this degeneration include impaired vibration 
discernment, spastic paraparesis, and extensor plantar response 7.  In addition, optic 7, 
peripheral, and cranial neuropathies are also possible 7,52.  Other research has documented 
peripheral neuropathy, which includes a case study of a patient with onset of symptoms 
in the hands, where all limbs were also affected 7.  It is important to differentiate between 
B12 deficiency neuropathy and neuropathy associated with aging or other conditions.  
Thus a young adult population is ideal when studying this neuropathy. 
Subclinical Vitamin B12 Deficiency 
 A large majority of current research on vitamin B12 focuses on the consequences 
of full deficiency, rather than subclinical deficiency or depletion.  Concern for the 
consequences of subclinical deficiency, however, have recently been increasing due to 
the inefficacy of supplement therapy on nervous system symptoms in an elderly subject 
with low vitamin B12 nutriture 7.  According to Obeid and Herrmann, subclinical 
deficiency is a common problem today 53.  Although the frequency of this subclinical 
deficiency is not clearly defined, but it is estimated that subclinical deficiency is 10 times 
more common than clinical vitamin B12 deficiency.  In addition, it is also believed that a 
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large number of individuals displaying subclinical deficiency may respond to 
supplements with a decrease in slight neurologic consequences 7.  Thus, identifying these 
patients and administering therapy before a more defined clinical deficiency rises is 
essential to prevent permanent neurological damage.  There are several problems thought 
to contribute to the commonality of this subclinical deficiency, including a low RDA for 
vitamin B12 (some research has even suggested that it be increased to 6 μg/day) and an 
overestimation of hepatic storage abilities 53.  It is currently not known the exact serum 
concentration at which these subclinical will disappear, particularly in the older 
population 8.  Thus, due to this prevalence of subclinical deficiency, a normal serum B12 
concentration would not necessary exclude vitamin B12 deficiency from the list of 
potential diagnosis.  Clinicians will likely examine metabolites such as MMA and 
homocysteine to reveal a deficiency in patients with suspected vitamin B12 deficiency 8.  
However, it is important to consider that other conditions may lead to an elevation in 
these metabolites, such as renal problems 8 or genetic disorders. 
Dexterity 
Dexterity is defined as the voluntary movements of the hands required to move or 
manipulate an object for a specific purpose 54.  Dexterity can be categorized into two 
different classifications, static or dynamic, based on grasping and manipulation 
requirements.  Static dexterity does not require grasping or manipulation.  An example of 
this is hitting something with a fist.  Dynamic dexterity requires both grasping abilities 
and manipulative skill 55.  Dynamic dexterity can be further subdivided into two types of 
dexterity: manual and fine finger dexterity.  Manual dexterity is the ability to move hands 
easily in a turning or placing motion.  Fine finger dexterity is the ability to skillfully 
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move and handle an object with the fingers 55.  Fine finger dexterity requires much more 
precise motion and coordination than manual dexterity. 
The decrease in myelination associated with vitamin B12 deficiency may be 
important for dexterity as the literature suggests possible connections between dexterity 
and myelination in adolescent-onset psychosis patients 10, dexterity and right cerebral 
white matter volume (white matter is bundles of myelinated axons in the brain 11 ), and 
primary motor cortex volume in healthy older adults 12.  These negative impacts on hand 
functionality can decrease the quality of life as daily activities, personal medical care, or 
activities related to work are all affected 13.  Subtle changes in dexterity may reveal 
subclinical deficiency which, if identified early, can aid in the prevention of serious 
complications of vitamin B12 deficiency such as impaired vision, personality changes 7, 
psychosis, depression, mania 8, and dementia-like illness 9. 
Purdue Pegboard Test 
 The Purdue Pegboard test is one of the most widely used tests to assess fine finger 
dexterity 55.  This test was originally designed to assess the dexterity aptitude of 
individuals interested in occupations requiring fine finger movements such as assembly 
positions or machine operators.  This test provided a much cheaper way to assess 
employees than other tests of the time 56.  The reliability of the Purdue Pegboard test has 
been examined in several studies for one-trial administration.  In a review of these 
studies, Buddenberg and Davis documented that the correlation coefficients of the 
subtests have ranged from 0.60 to 0.79 in both sexes, and up to 0.83 when only 
examining one sex 57.  In addition, investigators examining the test-retest reliability of 
one-trial administration with one week between tests of the Purdue Pegboard found ICCs 
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ranging from 0.37-0.70 for each of the Purdue Pegboard’s assessments 57.  Perhaps a 
better method of analyzing this would be assessing dominant vs. non-dominant hand, as 
hand dominance likely plays a role in dexterity scores.  The Purdue Pegboard is also 
administered in a 3-test bout, in which the reliability scores are predictably higher 56.  
However, a “practice effect” exists with this test 57, which makes administering the test 
multiple times in one sitting questionable.  Another important factor in test scores was the 
privacy of the test and knowledge of previous scores.  Both of these cases increased the 
competitiveness of participants in one study 57, which may ultimately affect the validity 
of the results.  Thus, the test should be conducted in a private room, and scores should not 
be shared with participants until after the completion of a study. 
 The Purdue Pegboard 
(pictured below) resembles a board 
game and is relatively simple and 
quick to administer.  The board has 
two parallel lines of holes down the 
center of the board four cups at the 
top.  The outside cups should contain 
half of the pins provided (~25).  The 
center-right cup contains washers 
and the center-left cup contains 
sleeves.  The test is administered in 
four parts: right hand, left hand, both 
hands, and assembly 56.  Prior to each 
Figure 1:  Purdue Pegboard with pegs for right hand 
dexterity test (top) and pieces for assembly test (bottom). 
   34
test, the subject is allowed to practice with 3-4 pieces before the time begins.  In addition, 
the subject should sit at a comfortable table around 30 inches off of the floor.  For both 
the right and left-hand tests, the subject is told to use only the respective hand to pick up 
one pin at a time and place it in the next consecutive hole as many times as possible 
during a thirty-second period.  For this test, the score is the number of pins placed in the 
board 56.  This score should be directly related to vitamin B12 status.  For the both hand 
test, the same procedure should be followed as the left and right test, but with both hands 
working simultaneously.  For this test, the score is equal to the number of complete pairs 
placed in the board 56.  The scores of the right hand, left hand, and both hand tests are 
added up to create the right plus left plus both hand score, which is commonly used in 
research 56.  The assembly test (bottom picture above) is a more complex task and 
requires subjects to place a pin chosen from the right cup with the right hand, a washer 
over the pin placed with the left hand, a sleeve over the washer placed with the right 
hand, and a final washer over the sleeve placed with the left hand.  For this task, the 
subject has 60 seconds to assemble as many towers as possible.  For this task, the score is 
equal to the number of pieces placed on the board 56. 
Functional Dexterity Test 
 The Functional Dexterity Test (FDT) is a commonly used assessment tool to 
evaluate manual dexterity in both adults and children 55.   
Several studies have examined the reliability of this test and have found it is a valid 
measurement tool in populations such as individuals with musculoskeletal diseases, 
rheumatology conditions, and neuropathy.  In addition, several studies have also found 
that the FDT is a valid tool to assess the association between dexterity and hand functions 
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such as handwriting and keyboard, as well as hand grip strength 55.  In addition, in a study 
conducted in healthy adults assessing the test-retest reliability of the FDT, investigators 
found an ICC of 0.94 for net time and 0.92 for total score 55.  In addition, investigators 
also found that demographic factors such as hand dominance and sex did not affect 
scores.  Age, however, did affect scores for individuals older than 50 years old 55.  Thus, 
when dexterity is examined as an outcome in a research study, a younger population 
should be used to avoid decreases in dexterity associated with age from confounding 
results.  Further, when examining dexterity in older adults, it is important to control for 
age in statistical analysis. 
 Like the Purdue 
Pegboard, the Functional 
Dexterity Test (pictured 
below) resembles a board 
game and is very simple to 
administer.  The test consists 
of a wooden board with 16 
holes, each with a peg.  The 
pegs are colored with different colors on the top and bottom.  The objective of the test is 
to turn all of the pegs over and place them back in their respective holes as quickly as 
possible.  The test must be conducted with each hand separately.  The test is scored by 
the number of seconds it takes for the participant to complete turning each of the pegs 
over 55.  Time penalties are added for any errors in completing the test: 5 seconds for each 
time the participant touches or rests on the board for support and 10 seconds if the 
Figure 2:  Functional Dexterity Test 
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participant drops a peg.  The total time without penalties is the net time and represents 
hand dexterity speed.  Adding the total time and the penalties gives the adjusted time, 
which represents the quality of the hand dexterity 55.  This score should be inversely 
related to vitamin B12 status.  Unlike the Purdue Pegboard test, the FDT test is typically 
reported as the dominant or non-dominant hand 55, rather than left or right. 
Balance 
 Balance can be measured by a multitude of analyses tools, including the force 
plate (FP) 58.  A laboratory grade force plate, such as the AMTI Accusway, is considered 
the “gold-standard” in measuring standing balance 59.  A force plate (such as the AMTI 
accusway) measures the force that a body exerts on the ground while in defined 
conditions (i.e. feet apart, feet together, one foot, etc.).  In particular, a force plate 
measures the center of pressure (COP) of this ground reaction force, and the displacement 
in this force over a specified period of time 58.   
According to Chaudhry et al., differences in COP displacements between two 
groups can be examined to compare balance.  Other variables, such as area, velocity, and 
distance traveled, can also be used to characterize stability.  However, there is still 
disagreement in the literature as to which variable produced by the FP most accurately 
portray one’s balance capabilities 58.  Medio-lateral displacement is also an additional 
variable commonly examined in force plate studies.  Interestingly, this variable has been 
shown to be associated with fall-risk in older adults 58. 
Although research regarding the association between vitamin B12 and postural 
control is largely lacking, the relationship between balance and peripheral neuropathy is 
well documented in the literature 60.  Most (if not all) of this research is conducted on 
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subjects with particular health conditions such as diabetes and cancer.  This change in 
balance is likely due to the decreased somatosensory feedback from the legs and feet, 
decreased proprioception, and decreased reaction time that occurs with peripheral 
neuropathy 60.  In severe cases, balance impairment due to neuropathy can lead to an 
increased fall risk 60,61.  One study examining balance in diabetic and non-diabetic 
women discovered significant differences between the mean amplitude of oscillation in 
both the anterior-posterior and medial-lateral direction, as well as the average speed of 
oscillation in the mediolateral direction 62.  A second study examining the differences in 
balance between a control group and breast cancer survivors suffering from 
chemotherapy-induced peripheral neuropathy found significant differences in center of 
pressure displacement.  The authors of this study also discovered a correlation between 
the balance displacement and neuropathy symptoms 61.  A third recent study that 
examined the impact of long-term vitamin B12 supplementation on fall risk in older 
adults did not document a decrease in fall risk over time or a difference in fall risk 
between the intervention and control group.  However the investigators did not examine 
any specific measures of balance in this study 63.    The findings of research studies such 
as these warrant investigation into the effects that vitamin B12 deficiency may have on 
neuropathy and precise measures of postural control in symptomatic and asymptomatic 
individuals. 
Vibration Sensitivity 
 Decreases in vibration proprioception and vibration sense are physical symptoms 
of vitamin B12 deficiency related to changes in the spinal cord52, specifically white 
matter deterioration in the posterior and lateral columns of the spinal cord.  This can lead 
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to decreases in vibration sense because these columns contain sensory fibers which aid in 
vibration proprioception and, according to Simpson et. al, are especially sensitive to 
vitamin B12 deficiency 64.  In addition, deterioration of the peripheral nervous system can 
contribute to cutaneous sensory loss 52, such as loss in vibration sensitivity. 
Several studies have documented the decrease in vibration proprioception due to 
vitamin B12 deficiency.  One case study identifies a 57-year-old women with serum B12 
concentrations within the normal range (albeit in the lower end) who presented with 
biochemical and neurological symptoms consistent with B12 deficiency, including 
impaired vibration sense 52.  A second study examining the prevalence of vitamin B12 
and folate deficiency in the Indian state of Maharashtra documented decreased vibration 
sense in 5 subjects.  However, of the subjects with serum B12 concentrations less than 
200 pg/mL, 4 out of 4 subjects experiencing decreased vibration sense only experienced 
this in lower limbs.  The method used to examine vibration sense was not mentioned by 
the authors of this study 65.  A third study examined the prevalence and clinical symptoms 
of vitamin B12 deficiency in psychiatric patients at a mental health intuition in Uganda.  
This study found that 12 patients had absent vibration sense, and that this was 
significantly correlated with low vitamin B12 (<240 pg/mL) in these patients.  However, 
as these patients were residing in a mental health hospital, it is possible that they had 
other confounding neurological conditions at the time of the study.  In addition, 
investigators did not disclose the method used to determine vibration sensation 66.  A 
fourth study examining the vibration sensitivity in individuals with a prior gastrectomy 
found that those who had low serum B12 concentrations had a significantly higher 
vibration threshold (inverse relationship) than those who had normal B12 concentrations.  
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Further, these individuals displayed a decrease in vibration thresholds (increased 
vibration sensitivity) when treated with vitamin B12 67.  However, individuals with 
“inadequate therapy” or injections every month at most, did not display signs of 
improvement.  The author of this study did mention, however, that although vibration 
sensitivity did improve, markers of myelopathy (such as Romberg’s sign) remained 
unchanged 67. 
Applications in Diabetes 
 The relationship between vitamin B12 and vibration sensitivity may have 
applications in the field of diabetes care and research.  Vitamin B12 has been suggested 
as a treatment method for diabetic neuropathy (DN) 68.  Diabetic neuropathy is the 
primary cause of neuropathy in developed countries, and contributes to more diabetes-
related hospitalizations than any other symptom of diabetes.  Diabetic neuropathy can be 
extremely painful, with sensations ranging from tingling to burning, freezing, or stabbing 
pain 68.  
A few studies have examined the effect of vitamin B12 supplementation on 
diabetic neuropathy, including one out of a diabetes clinic in Arak, Iran.  This study 
examined the difference between intramuscular vitamin B12 injections (2000 µg) and 
oral nortriptyline pills, an antidepressant drug commonly prescribed to treat DN.  In a 
single-blind trial with 100 subjects, the investigators discovered that the pain, tingling, 
and paresthesia symptoms decreased significantly more (P<0.001) in the intervention 
group than the standard of care group.  However, other characteristics of diabetic 
neuropathy such as diminished vibration, position, or nerve conduction speed did not 
differ significantly across group or time 68.  Interestingly, the authors mentioned that 
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some of the individuals who displayed improvement with the administration of vitamin 
B12 had normal serum B12 pre-test results, illustrating the possibility of improvement in 
DN for all individuals, not just those who are vitamin B12 deficient 68. 
As Metformin is commonly prescribed to aid in diabetes control, the diabetic 
population may be at a higher risk for developing vitamin B12 deficiency than the non-
diabetic population 68.  Regardless, there are still no formal guidelines regarding vitamin 
B12 supplementation in diabetic patients.  Some research suggests that multivitamin 
supplements do not contain enough cobalamin, as multivitamin use did not correct the 
inadequate vitamin B12 status in long-term Metformin users.  Kibirige and Mwebaze 
suggest that a yearly 1000 ug dose of vitamin B12 may be enough to normalize serum 
B12, however they fail to identify a suggested method of supplementation 69.  Given the 
growing number of individuals diagnosed with diabetes, understanding the vitamin needs 
of these patients is of the utmost importance. 
Vibratron II – Vibration Sensitivity Tester (Physitemp) 
In the aforementioned study conducted by Talaei et al., a 128 Hz tuning fork was 
used to examine vibration sensitivity 68.  This method, however, is not ideal, as the 
frequency cannot be altered.  More adaptable measures such as the Vibratron II are ideal 
for measuring vibration sensitivity because the vibration intensity can be decreased in 
small intervals to determine the vibration threshold, a reflection of the lowest vibration 
frequency sensed, of the patient or study subject. 
The Vibratron II (pictured below) has been approved by the FDA for diagnostic 
use in determining cutaneous sensory loss 70.  In addition, according to a 2011 article, the 
Vibratron II is a useful tool in the detection of neuropathy in type 1 diabetic patients 71.  
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Prior research has examined 
the use of the Physitemp 
Vibratron II in examining 
vibration thresholds and 
neuropathy related to diabetes 
72-75, chemotherapy agents 76, 
and multiple sclerosis 77,78 with 
positive results.  However, no 
research has yet been conducted using the Vibratron II to examine the relationship 
between vibration threshold and serum B12 concentrations.  
The Vibratron II is composed of two testing blocks, labeled A and B, with two 
small rods on the top of each testing block.  Both testing blocks are attached to a central 
control device that governs the vibration intensity of the rods on the testing blocks, as 
well as the testing block selection.  One switch on the control unit determines the test 
block selection, while a second dummy switch is present to prevent subject knowledge of 
switching between testing blocks.  The vibration sensitivity test can be conducted at 
either high-resolution (0-6.5 vibration units, or 0-20 microns) or low-resolution (6.5-19.9 
vibration units, or 20-200 microns) frequencies.  High-resolution frequencies vibrate at a 
much faster rate and are more difficult to detect than low-resolution frequencies. 
Before the test begins, participants are instructed to use only the pointer finger on 
their dominant hand, be consistent with pressure throughout the test (enough pressure to 
begin to turn the fingernail yellow), to touch each rod for only one second, to touch each 
rod only once, and to touch A then B consecutively.  The test begins at a predetermined 
Figure 3:  Vibratron II – Vibration Sensitivity Tester 
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vibration intensity at which most participants are likely to sense.  The participants are 
allowed 5 attempts at this intensity to become comfortable with the test before the data 
collection begins.  If the participant correctly identifies the vibrating rod at all 5 switches, 
then testing will proceed.  Throughout the trial, the test administrator randomly switches 
between testing blocks, while using the dummy switch to ensure a switch is flipped after 
each attempt.  When a participant correctly identifies the vibrating rod, the vibration 
intensity for the next attempt is decreased by 10%.  If a participant incorrectly identifies 
the vibrating rod, that intensity is repeated.  After two incorrect identifications, the 
intensity is increased by 10% and the test will continue.  If an incorrect identification is 
followed by a correct identification, one more attempt is made at that intensity.  To 
eliminate the likelihood of a streak of correct guesses, all intensities below 0.7 vibration 
units (VU) will be repeated twice.  After five incorrect identifications, the test is 
completed.  The vibration units of the five errors and the five lowest scores are compiled, 
with the highest and lowest of these numbers thrown out to eliminate outliers.  The 
vibration threshold in VU is the average of these eight scores.  This vibration threshold 
can also be converted to microns. 
Supplementation 
 Currently, research examining vitamin B12 supplementation is sparse, as much of 
the data is subsidiary information reported in studies examining other factors.  However, 
much of the data available shows that deficiency rates in supplement users are still much 
higher than expected 1.  However, in one of these studies, the supplement users were 
removed from statistical analysis due to the small number of individuals in this group 41.  
In a larger second study, which consisted of 689 adult male participants of differing 
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dietary habits, only 19% of vegetarians and vegans, compared to 4% of omnivores, 
reported regularly taking a vitamin B12 containing supplement 43.  Of the supplement 
users, 89% of vegetarians and 63% of vegans consumed 1.5 μg of vitamin B12 per day.  
This is surprising as many of those taking supplements were still well below adequate 
consumption.  Interestingly, however, the investigators of this study did not find a 
significant difference between the serum B12 levels of supplement users and non-users in 
each dietary group 43.  Although the authors acknowledge that this could be due to a 
reporting error, this discrepancy also suggests a problem with efficacy or absorption of 
vitamin B12 supplements 43.  Some studies reveal that vitamin B12 supplements should 
be administered in mega-doses, even up to 100 times the current RDA 1. 
 Oral vitamin B12 supplementation is typically recommended for individuals at 
risk for deficiency, such as vegetarians or those who have had a gastrectomy.  In cases of 
deficiency, however, clinicians recommend a different supplementation regimen 8.  
Typically, 1 mg/day of intramuscular vitamin B12 injections is followed by 1 mg/week 
for one month, then 1 mg/month for the duration of the patient’s life.  According to 
Briani et al., oral doses of 1-2 mg/day will suffice for individuals who prefer to avoid 
maintenance injections.  However, this is typically only prescribed after body stores have 
been normalized by initial injections 8. 
If a prescribed supplement regimen is rigorously adhered to, symptoms of vitamin 
B12 deficiency begin to resolve soon after supplementation begins, with all abnormal 
hematologic symptoms resolving within 8 weeks 8.  The improvement in neurologic 
symptoms after treatment, however, is much more varied.  Although treatment typically 
leads to some improvement in neurologic symptoms, some residual effects may still 
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remain.  However, the literature generally supports the idea that early treatment yields the 
best results 8. 
Although there have been many vitamin B12 supplementation studies conducted, 
few examine the effects of supplementation in asymptomatic individuals.  One recent 
study examined the effect of on intramuscular vitamin B12 injection on nerve conduction 
speed in deficient, yet asymptomatic, elderly adults 79.  Investigators measured nerve 
conduction speed of the sural nerve (calf region) on both legs, as well as the median 
nerve (forearm) on the right arm before and after a B-vitamin complex containing 10mg 
of cobalamin.  The results of this study indicated a significant improvement in sural nerve 
conduction speed, which the investigators attribute to the vitamin B12 supplement.  
Although improvements in the sural nerve were clear, changes in the median nerve were 
less not well-established 79.  However, as both niacin and vitamin B6 were also included 
in the injection, it is possible that these vitamins also played a role in the improvement of 
nerve conduction speed.  Still, this study exhibits the need for further investigation of 
vitamin B12 supplementation on nerve conduction speed and other measures of 
peripheral nerve function.  Further, Brito et al. suggests that peripheral nerve conduction 
measurements may be the best method of detecting sub-clinical B12 deficiency 79. 
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CHAPTER 3 
METHODS 
Participants 
 Healthy vegetarian adults were recruited for this study through social media 
outreach, e-mail LISTSERVs, vegetarian support groups, and flyers posted at ASU and 
vegan restaurants.  Study advertising materials included the purpose of the study, age and 
dietary habits of participants needed, location for the study (Arizona State University 
downtown Phoenix campus), general time availabilities, and compensation information.  
Inclusion criteria included a willingness to travel to the Downtown ASU Nutrition 
laboratory for study visits.  Other qualifying criteria included age, diet habits and 
medication use.  This study was submitted to and approved by the Institutional Review 
Board Committee at Arizona State University.  All participants reviewed an informed 
consent statement prior to beginning the screening survey, and signed a detailed written 
consent form prior to official enrollment in the study.   
Participants were 19-40 years of age and represented a young adult population, 
which was the focus of this investigation.   Because B12 is only present in animal 
products 6, vegetarians and vegans are more likely than omnivores to be deficient in 
vitamin B12.  All participants adhered to their respective vegetarian or vegan diet for at 
least 3 years, a criteria based on the knowledge that there is an increased prevalence of 
vitamin B12 deficiency for vegans and vegetarians who had adhered to their diet for 2-4 
years 1.  In addition, the liver is known to store up to 3mg of vitamin B12, which can 
sustain the body above a state of depletion for 3-5 years 20. 
   46
Since certain medications are known to affect vitamin B12 metabolism, 
volunteers were asked to report if they regularly used the following medications: proton 
pump inhibotors (i.e. Nexium®, Prevacid®, Prilosec®) 80, anticonvulsants 81, potassium 
chloride 82, colchicine, certain antibiotics (neomycin), biguanides (Metformin) 8, and 
nitrous oxide 83.   Volunteers with medical conditions that would prevent safe completion 
of all aspects of this study, as well as those with nervous system disorders, were also 
excluded from participation.  These conditions include severe arthritis, severe carpel 
tunnel syndrome, hemophilia, and neurological movement disorders (i.e. Parkinsons, 
multiple sclerosis).  In addition, participants diagnosed with pernicious anemia, an 
autoimmune disease that prevents B12 absorption, were excluded. 
Study Design 
Screening:  An online survey was used to screen participants.  Prior to beginning 
the survey, participants were prompted to review an informed consent statement.  
Individuals were informed that, by continuing with the survey, they agreed to participate 
in the screening process.  This initial screening provided information regarding the 
respondents’ contact information, age, dietary habits (omnivore, lacto-ovo vegetarian, or 
vegan), duration of dietary habits, medical conditions that prevent participation in the 
study, medication use, ability to commute to the study location, and scheduling 
availability.  Respondents also were asked to acknowledge that, if they choose to 
participate in the study, they must arrive having fasted from food and drink (with the 
exception of water) for 8 hours prior to the scheduled study visit.  Selection options for 
this statement included “I Agree and am medically capable of fasting for 8 hours”, “I do 
not agree (select this option if you are medically unable to fast for 8 hours)”, and “I 
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choose not to answer”.  If the survey respondents met the criteria to be included in this 
study, they were contacted by e-mail (or phone if necessary) to schedule a study visit. 
Study Visit #1.  Participants were sent e-mail reminders 24 hours before the study 
visit regarding the location and time of their study visit, as well as a reminder to fast for 8 
hours prior to meeting with investigators.  The study visit began with investigators 
providing the participants with an informed consent document.  After participants read 
and signed the informed consent document, participants were assigned a subject number 
for de-identification of the data to protect participant privacy.  Height and weight were 
then measured.  After investigators had confirmed that participants fasted for 8 hours, a 
10 ml blood sample was collected via venous blood draw by a trained phlebotomist.  
Upon completion of the blood draw, snacks were provided to participants while they 
rested and completed a health history questionnaire and food frequency questionnaire.  
The health history questionnaire asked information regarding demographic characteristics 
(i.e. sex, age, race, ethnicity, education background, household income bracket, etc.), diet 
history, supplement history, and incidence of major disease. After participants completed 
the forms and finished their snacks, participants were asked to confirm a lack of 
hypoglycemic symptoms such as feeling “shaky, lightheaded, or hungry”.  Next, 
participants engaged in four functional tests.  Directions were read to participants while 
investigators demonstrated each test (see literature review and appendices B-E for more 
detailed instructions on the tests discussed below in steps 1-4). 
1. Balance:  Participants were asked to stand on the AMTI Accusway force plate 
with their feet at a 30˚ angle.  They were instructed to stare at a fixed point on the 
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wall (about eye level) while staying as still as possible for one minute.  Their 
center of pressure sway was analyzed during this period. 
2. Vibration Sensitivity:  Participants were instructed to touch two rods, in sequence, 
and determine which rod was vibrating.  Investigators randomly switched which 
rods were vibrating, while decreasing the vibration intensity throughout the test.   
3. Purdue Pegboard test:  Participants were asked to place small metal pins into a 
line of holes in sequence, as quickly as possible in 30 seconds.  Participants will 
complete the pegboard test 3 times each with their right hand, left hand, and both 
hands.  Participants will then complete an assembly test, where they created small 
towers with metal washers and sleeves, 3 times with both hands for 60 seconds 
each. 
4. Functional dexterity test:  Participants were instructed to turn over all wooden 
pegs on a board as quickly as possible with their dominant hand.  The test was 
then repeated on their non-dominant hand.  Net time (time to turn over all pegs) 
and the total score (net time + time penalties) will be recorded for this test. 
Upon completion of the functional testing, participants were debriefed and offered 
compensation for their time ($5 Target® gift cards). 
Study Visit #2:  Twenty-nine of the initial participants for visit #1 were invited 
back to participate in a follow-up study.  Twenty-five of these participants enrolled in the 
follow-up study.  After serum samples were analyzed, these participants were stratified 
by age, gender, BMI, and vitamin B12 status and randomly assigned to either the 
intervention or control group, and After consent forms were signed, participants were 
given bags containing 56 pills (500 mcg Nature Made™ B12 or placebo of 250mg 25% 
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Acetic Acid Nature’s Life™ apple cider vinegar pills), a supplement consumption log, 
and a username and password for ASA24 (an online, 3-day diet record log).  Investigators 
were blinded to the contents of the bag.  Participants were instructed to consume one 
supplement each day for eight weeks.  Participants were scheduled for study visit #3 at 
this study visit.  Throughout the 8 weeks, emails were sent to remind participants take 
their supplements and complete their 3-day diet record.  An 8 week time line was selected 
based on the normalization of blood count when introducing B12 supplements to 
deficient patients 7,8.  
The vitamin B12 dosage selected for this intervention trial (1000 mg/d) is safe 
based on the fact that there is no upper limit of vitamin B12 84.  One study examining the 
effects of B12 on homocysteine levels as well as incidence of acute myocardial infarction 
in individuals 30-85 years of age found no adverse side effects of participants ingesting 
0.4 mg of B12 daily (167x the DRI) for 40 months 85.  In addition, a second study 
examining the effects of vitamin B12 supplementation homocysteine concentrations and 
incidence of stroke and coronary artery disease in individuals >55 years of age found no 
adverse side effects of participants ingesting 1.0 mg of B12 daily (2400x the DRI) for 5 
years 86.   
Study Visit #3:  Participants were sent e-mail reminders 24 hours before the study 
visit regarding the location and time of their study visit, as well as a reminder to fast for 8 
hours prior to meeting with investigators.  Investigators collected supplement bags with 
remaining supplements and supplement consumption logs.  Height and weight were also 
measured.   The same protocol for study visit #1 was repeated for the blood draw, 
vibration sensitivity, balance, and dexterity tests.  Upon completion of the functional 
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testing, participants were debriefed and offered compensation for their time ($20 Target® 
gift cards). 
Lab Assays.  All laboratory analysis took place in the School of Nutrition and 
Health Promotion Laboratory in the Arizona Biomedical Complex building on the 
Arizona State University downtown Phoenix campus.  Assays were overseen by the 
Senior Research Nurse and Radiology Technologist.  After the blood samples were 
collected, they were centrifuged in order to separate the plasma that was stored in the 
laboratory freezers until analyses. The remaining components of the blood were properly 
discarded.  Duplicate assays were performed for each serum sample using a B12/Folate 
Radioasay kit (SimulTRAC-SNB Vitamin B12/Folate RIA Kit; MP Biomedicals; Santa 
Ana, CA) and gamma radiation detection (Wallac Wizard Gamma Counter 1470; Perkin 
Elmer; Waltham, Massachusetts).  Each kit permitted the analysis of 32 duplicate 
samples over a 4 hour time period.  This assay provided cobalamin, holo-transcobalamin 
II (TCII), and folate serum concentration information.  Individual participant sample 
pairs with a high coefficient of variation (>10%) were re-run in order to prevent 
laboratory error. 
Serum vitamin B12 and folate concentrations are determined by a radioassay 
technique that measures the proportion of both the endogenous vitamin and the 
exogenous radiolabeled vitamin bound to high affinity, specific binding compounds.  In 
this assay, BIORAD Lyphocheck® human serum assay standards and controls are used 
to develop the standard curve.  To examine total serum vitamin B12 concentrations, 200 
μL of vortexed serum, standards, and controls are added to empty12x75 mm 
polypropylene tubes (see Appendix F).  A mixture of the radiolabeled vitamins (B12 and 
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folate) and a Dithiothreitol solution is added to the serum samples.  This mixture is then 
vortexed and incubated at room temperature under a cover of aluminum foil for 15 
minutes.  Next, 100 μL of extracting reagent is added to the mixture, which is again 
vortexed and incubated at room temperature under a cover of aluminum foil for 10 
minutes.  The combination of the dithiothreitol and the alkaline pH of the extracting 
reagent functions to degrades all proteins bound to vitamin B12 and folate.  Thus, the 
resulting mixture contains free endogenous and exogenous vitamin B12 and folate.  
Blank reagent (1000 μL) is then added to one sample (two tubes) to act as a control for 
the addition of the binding reagent.  Next, 1000 μL of the binding reagent is added to all 
standard, control, and reference tubes.  This binding agent must be vigorously shaken 
before transferring to the sample tubes, as it tends to clump and stick to the walls of its 
container.  The binding reagent contains both a purified intrinsic factor (B12 binder) and 
a purified folate binder.  The mixture is then vortexed and incubated at room temperature 
for 1 hour under aluminum foil.  After 1 hour, the mixture is centrifuged at 4°C for 10 
minutes at 3000 rpm.  Next, the tubes are removed from the centrifuge and handled 
gently so as not to disturb the solid pellet at the bottom of the tube.  The supernatant 
fluid, which contains excess serum compounds and unbound radiolabeled vitamins, is 
removed by decanting each tube and wiping excess fluid from the rims of the tubes.  
Finally, the samples are run through the gamma counter, which provides printouts 
detailing the standard curves and values for each sample’s total serum B12 and folate.  As 
each binder has a higher affinity for the endogenous forms of the vitamins, the amount of 
radioactive isotopes in the final pellet is inversely proportional to the serum concentration 
of the vitamin B12 and folate.  
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Transcobalamin II serum concentration is evaluated using the technique 
developed by Das et al 87.  In this assay, 3 grams of microfine silica (silicon dioxide) 
from Sigma-Aldrich is combined with 20 mL of distilled water.  This mixture is placed 
on a stir plate and thoroughly mixed.  The edges of the container are continually scraped 
with a glass rod to prevent the silica from clumping.  While stirring, 100 μL of the silica 
slurry is combined with 500 μL of serum.  The slurry is the incubated at room 
temperature for 10 minutes under a cover of aluminum foil.  Next, the mixtures are 
centrifuged at 5000 X g for 10 minutes.  After carefully removing the samples from the 
centrifuge, the supernatant fluid is transferred to separate tubes.  These samples are then 
analyzed for B12 using the above radioassay technique.  As the silica binds to holo-
transcobalamin II, the supernatant liquid in this portion of the assay will represent 
transcobalamin I and III.  Thus, to determine the serum concentration of TCII, the results 
of this assay are subtracted from the results of the total serum B12 assay. 
Statistical Analysis 
 The sample size was calculated using 80% power and an α of 0.05.  Based on the 
below table, the ideal sample size for this study is 45 subjects, accounting for 20% 
attrition to ensure a final sample size of 36 (18 subjects per group).  The sample size was 
calculated based on the primary outcome variables of dexterity and vibration sensitivity.  
Sample size calculations based on median motor nerve conduction velocity are included 
below, as this outcome variable was originally intended to be included as a part of this 
study.  Measuring nerve conduction velocity in a non-invasive and cost-efficient manner, 
however, was deemed unfeasible.  Therefore, nerve conduction velocity* was removed 
from this study.  The standard deviation for vibration sensitivity was taken from the 
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population average documented in the Physitemp Vibratron-II Operating Manual.  The 
minimal detectable differences were calculated using the difference between the 
population average (0.7) in the Physitemp Vibratron-II Operating Manual and the average 
vibration threshold (1.05) documented in Martin et al.’s study examining 1,177 diabetic 
adults. 
Sample Size Calculations 
Outcome 
Variable 
Standard 
Deviation 
Source 
Minimal 
Detectable 
Difference 
Source 
Sample 
Size 
Purdue 
Pegboard: 
Right-
hand 
dexterity 
1.33 
Preliminary 
Data (2nd-
year study) 
1.3 Telles et al. 88 36 
Vibration 
Sensitivity 
0.4 
Physitemp 
Vibratron-
II 
Operating 
Manual 
.305 
Physitemp 
Vibratron-II 
Operating 
Manual, Martin 
et al. 89 
44 
Median 
motor 
nerve 
conduction 
velocity* 
4.2 
Sahin et al. 
90 
5.7 Sahin et al. 90 20 
Table 3. Sample size calculations utilizing dexterity and vibration sensitivity.  
Median motor nerve conduction was used to calculated sample size for the 
study before it was removed as an outcome variable. 
 
Statistical analysis was conducted using the Statistical Package for Social 
Sciences (SPSS 21 for Windows, 2010, Chicago IL) software program.  Normality was 
assessed, and non-normal data was transformed.  Demographic information was compiled 
and presented using data from the initial screening survey, as well as the health history 
questionnaire.  Data is reported as mean ± SD. 
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Cross Sectional 
Pearson’s correlations were conducted for all parametric and normalized data.  
Spearman’s correlations were conducted for non-parametric data points.  Partial 
correlations, controlling for folate, were also conducted for all data points.  For non-
parametric variables, the most parametric transformation was used in partial correlation 
analyses. 
Outcome variables were compared between several groups: vegetarians and 
vegans, short-term and long-term diet adherence, supplement users and non-users, and 
combined supplement users and B12/B-complex supplement users.  For normally 
distributed variables, group differences were calculated using independent t-tests.  For 
non-parametric variables, group differences were calculated using Mann-Whitney U 
tests. 
Intervention 
Two-way repeated measures ANOVAs were used to test mean differences for 
each of the outcome variables (vibration sensitivity, balance variables, functional 
dexterity, Purdue pegboard dexterity) by main effects of time (pre, post) and group 
(intervention, control), as well as an interaction effect (time x group).  General linear 
models were also used to test mean differences for the main and interaction effects after 
adjustment for covariates.  
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CHAPTER 4 
RESULTS 
Cross-Sectional Data Analysis 
Of the 351 individuals who responded to a screening survey, 105 individuals 
qualified for this study.  Individuals were screened out of the study if they were an 
omnivore, had not adhered to a vegetarian diet for at least three years, had a history of 
cancer or diabetes, were not between the ages of 18 and 40, were pregnant or 
breastfeeding, had false nails that extended past the fingertips, or were unable/unwilling 
to provide blood samples and commute to study sites.  Thirty-eight subjects were 
ultimately enrolled in the study.  The majority of qualified participants, who qualified but 
did not enroll, were not enrolled due to lack of e-mail responses or scheduling 
availability. 
 
Figure 4. Participant recruitment and retention for the cross-sectional portion of thus 
study. 
Demographic characteristics of the 38 enrolled participants are shown in Table 4 
and Table 5 below.  The majority of participants were Caucasian females who had been 
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vegan for more than five years.  The average age of participants is 28.4 y.  The average 
BMI is 22.0 kg/m2, falling into the normal weight BMI category. 
Table 4: Demographic frequencies in the total study 
population.  
Variable n  (%) 
Total 38 
Gender  
Male 9 (23.6) 
Female 29 (76.3) 
Ethnicity  
Native American 0 
African-American 0 (0) 
Caucasian 32 (84.2) 
Hispanic 1 (2.6) 
Asian 5 (13.2) 
Other 0 
Diet  
Vegan 23 (60.5) 
Lacto-Ovo Vegetarian 15 (39.5) 
Diet Length  
2-3 years 1 (2.6) 
3-5 years 15 (39.5) 
More than 5 years 22 (57.9) 
Activity  
Not active 0 (0) 
Somewhat active 13 (34.2) 
Active 15 (39.5) 
Very Active 10 (26.3) 
 
 
 
Table 5: Demographic characteristics (Mean ± SD) of the 38 subjects 
enrolled in the cross-sectional portion of the study. 
Variable Mean SD 
Age (y) 28.4 5.5 
BMI (kg/m2) 22.0 2.7 
Physical Activity (MET minutes/week) 62.6 6.5 
Alcohol consumption (drinks per week) 1.4 2.3 
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Shapiro-Wilk normality tests of outcome variables revealed normal distribution 
for the following variables: some balance markers (x-axis maximum velocity, average 
velocity, path length), all Purdue Pegboard variables (right-hand average, left-hand 
average, both hand average, right/left/both hand average, assembly average), one 
functional dexterity test variable (right hand raw), and transcobalamin II.  The following 
variables were abnormally distributed: some balance markers (y-axis maximum velocity, 
area effective, 95% area), vibration threshold (in vibration units and microns), most 
functional dexterity test variables (right hand adjusted, left hand raw, and left hand 
adjusted), folate, and vitamin B12.  Functional dexterity test raw scores is the time 
(seconds) to complete each test without any time penalties added.  A (*) in the tables 
below indicates non-parametric distribution.  For these values, non-parametric tests were 
used to assess outcomes. 
Table 6: Normality Testing of Major Outcome Variables 
Outcome Variable Significance Transformation Significance 
Balance 
Vy Max 0.028* Inverse 0.000* 
Vx Max 0.091   
V average 0.119   
Path Length 0.119   
Area Effective 0.000* Logarithm 0.878 
Area 95 0.000* Logarithm 0.656 
Vibration 
Threshold 
VT (Vibration Units) 0.047* Square Root 0.016* 
VT (Microns) 0.000* Square Root 0.035* 
Fine 
Dexterity  
Purdue 
Pegboard 
Right Hand 0.828   
Left Hand 0.615   
Both Hands 0.494   
Right/Left/Both Hands 0.707   
Assembly 0.724   
Manual 
Dexterity 
Functional 
Dexterity 
Test 
Right Hand Raw 0.199   
Right Hand Adjusted 0.005* Logarithm 0.385 
Left Hand Raw 0.016* Logarithm 0.200 
Left Hand Adjusted 0.006* Logarithm 0.104 
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Biochemical 
Data 
Folate 0.005* Logarithm 0.864 
B12 0.000* Logarithm 0.661 
TCII 0.090   
 
With logarithmic transformations, the distribution of the following variables was 
normalized: area effective, area 95, FDT right hand adjusted, FDT left hand raw, FDT 
left hand adjusted, folate, and B12.  Vibration threshold (in both vibration units and 
microns) and Vy max were not able to be normalized with logarithmic, inverse, and 
square root transformations.  
The relationship between serum B12 and TCII displayed a strong correlation 
(R=0.667) (figure 5).  
 
Figure 5:  Association between serum TCII and B12.  R values obtained from parametric 
correlations with TCII and log transformed B12. 
The balance, dexterity, and vibration sensitivity mean results are displayed below.  
Table 7 displays group differences by diet, table 8 displays group differences by diet 
length, table 9 displays group differences between supplement users and non-users, and 
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Table 10 displays group differences between those taking combined supplements (B12 
combined with other nutrients) and stand-alone B12 or B-complex supplements.  Lower 
values are desired for the following variables: Vy max, Vx max, V average, path length, 
area effective, area 95, VT, right hand adjusted, and left hand adjusted.  Higher values are 
desired for the right hand, left hand, both hands, right/left/both hands, assembly, folate, 
B12 and TCII.  Confounder analysis revealed that gender is a confounder for Vx max and 
the Functional Dexterity Test right hand adjusted outcomes.  In addition, BMI is a 
confounder for the Purdue Pegboard assembly score.  In the tables below, higher values 
are desired for the variables marked with an (**).  Lower values are desired for all other 
variables. 
Table 7. Mean Difference for Outcome Measures between Vegans and Vegetarians 
Variable Total (n=38) Vegan (n=23) Vegetarian (n=15) p 
 Mean SD Mean SD Mean SD  
Vy Max (in/sec) -3.19 1.42 -3.31 1.60 -3.00 1.12 0.643 
Vx Max (in/sec) 3.01 1.30 3.05 1.14 2.96 1.53 0.584 
V average (in/sec) 0.939 0.335 0.935 0.353 0.945 0.318 0.930 
Path Length (in) 56.4 20.1 56.1 4.5 56.7 19.1 0.929 
Area Effective 
(in2) 
1.18 1.27 1.12 1.08 1.27  1.55 0.920 
Area 95 (in2) 2.59 2.30 2.60 2.44 2.59 2.16 0.894 
VT (Microns) 0.394 0.306 0.424 0.366 0.351 0.190 0.881 
Right Hand (pins 
per 30 sec)** 
15.4 1.6 15.4 1.4 15.5 1.8 0.786 
Left Hand (pins 
per 30 sec)** 
14.6 1.6 14.7 1.5 14.3 1.9 0.517 
Both Hands (pins 
per 30 sec)** 
12.4 1.5 12.5 1.4 12.3 1.6 0.693 
Right/Left/Both 
Hands (pins per 
30 sec)** 
42.4 4.1 42.6 3.6 42.1 4.9 0.766 
Assembly (pieces 
per 60 sec)** 
28.9 3.9 28.7 3.7 29.3 4.1 0.226 
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Right Hand 
Adjusted 
(seconds) 
23.3 6.0 23.9 6.3 22.4 5.5 0.220 
Left Hand 
Adjusted 
(seconds.) 
26.9 9.1 26.4 10.0 27.5 8.0 0.462 
Folate 
(nmol/L)** 
42.3 19.0 40.4 17.6 45.0 21.2 0.444 
B12 (pmol/L)** 354.9 224.4 378.7 261.9 320.0 156.4 0.653 
TCII (pmol/L)** 55.5 37.7 63.3 39.6 44.4 32.7 0.128 
 
There was no significant difference in outcome variables between vegetarians and 
vegans.  Of the 23 vegan participants, ten had adhered to their diet for more than 5 years.  
In addition, 14 of the 23 vegan participants reported taking B12 containing supplements.  
Of these 14 vegan supplement users, 7 reported taking B12 or B-complex supplements.  
Of the 15 vegetarian participants, 12 had adhered to their diet for more than 5 years.  In 
addition, 7 of the 15 vegetarian participants reported taking B12 containing supplements.  
Of these 7 vegetarian supplement users, 3 reported taking B12 or B-complex 
supplements.  Of the vegan participants, 14 supplemented with B12 containing 
supplements and 9 did not supplement with B12 containing supplements.  Of the 
vegetarian participants, 7 supplemented with B12 containing supplements and 8 did not 
supplement with B12 containing supplements. 
Table 8.  Mean Difference for Outcome Measures  by Length of Diet Adherence 
Variable Total (n=38) 3-5 years (n=16) > 5 years (n=22) p 
 Mean SD Mean SD Mean SD  
Vy Max (in/sec) -3.19 1.42 -2.95 1.34 -3.35 1.48 0.307 
Vx Max (in/sec) 3.01 1.30 2.72 1.23 3.22 1.33 0.194 
V average (in/sec) 0.939 0.335 0.925 0.338 0.949 0.340 0.834 
Path Length (in) 56.4 20.1 55.5 20.3 57.0 20.4 0.834 
Area Effective 
(in2) 
1.18 1.27 1.14 1.20 1.21 1.34 0.795 
Area 95 (in2) 2.59 2.30 2.48 2.66 2.67 2.07 0.483 
VT (Microns) 0.394 0.306 0.508 0.409 0.317 0.183 0.203 
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Right Hand (pins 
per 30 sec)** 
15.4 1.6 16.0 1.3 15.1 1.7 0.082 
Left Hand (pins 
per 30 sec)** 
14.6 1.6 15.5 1.6 13.9 1.3 0.003 
Both Hands (pins 
per 30 sec)** 
12.4 1.5 13.4 1.0 11.7 1.3 0.000 
Right/Left/Both 
Hands (pins per 
30 sec)** 
42.4 4.1 44.9 3.0 40.6 3.9 0.001 
Assembly (pieces 
per 60 sec)** 
28.9 3.9 30.7 3.2 27.7 3.9 0.035 
Right Hand 
Adjusted 
(seconds) 
23.3 6.0 22.3 4.9 24.0 6.6 0.268 
Left Hand 
Adjusted 
(seconds.) 
26.8 9.1 23.4 6.2 29.2 10.2 0.042 
Folate 
(nmol/L)** 
42.3 19.0 46.7 22.6 39.2 16.0 0.329 
B12 (pmol/L)** 354.9 224.4 390.0 276.6 331.0 184.0 0.498 
TCII (pmol/L)** 55.5 37.7 51.3 32.4 58.4 41.4 0.583 
 
There was a significant difference between the short-term (3-5 years) and long-
term diet adherence groups for all Purdue Pegboard outcomes measuring fine dexterity, 
except one.  Individuals in the long-term diet adherence group scored significantly less on 
left hand dexterity (p=0.003), both hand dexterity (p<0.001), right/left/both hand 
combined dexterity (p=0.001), and the assembly test (p=0.010).  The difference between 
groups for right hand dexterity is trending towards significance (p=0.082).  There was no 
difference between the long-term and short-term diet adherence groups for any other 
balance, vibration sensitivity, or manual dexterity variables.  Although there was a 
significant difference in fine dexterity outcomes between the diet adherence groups, there 
was no significant difference in vitamin B12 or TCII values between the two groups.  
However, the mean serum B12 for those who had adhered to their diet for more than five 
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years (331.0 ± 184.0) was lower than the mean serum B12 for those who had adhered to 
their diet for 3-5 years (390.0 ± 276.6).  The TCII values for both diet adherence groups 
were similar, but the mean TCII for the short-term diet adherence group (51.3 ± 32.4) 
was lower than the mean TCII for the long-term adherence group (58.4 ± 41.4). 
Table 9.  Mean Difference for Outcome Measures Between Participants Taking and 
Not Taking Vitamin B12 Containing Supplements 
Variable Total (n=38) Taking  (n=21) Not Taking (n=17) p 
 Mean SD Mean SD Mean SD  
Vy Max (in/sec) -3.19 1.42 -3.08 0.946 -3.31 1.85 0.927 
Vx Max (in/sec) 3.01 1.30 2.89 1.02 3.16 1.59 0.484 
V average (in/sec) 0.939 0.335 0.960 0.326 0.915 0.354 0.685 
Path Length (in) 56.4 20.1 57.6 19.6 54.9 21.2 0.685 
Area Effective 
(in2) 
1.18 1.27 1.04 0.920 1.35 1.61 0.709 
Area 95 (in2) 2.59 2.30 2.37 1.95 2.85 2.69 0.805 
VT (Microns) 0.394 0.306 0.344 0.227 0.454 0.377 0.246 
Right Hand (pins 
per 30 sec)** 
15.4 1.6 15.6 1.4 15.2 1.7 0.374 
Left Hand (pins 
per 30 sec)** 
14.6 1.6 14.9 1.7 14.2 1.5 0.265 
Both Hands (pins 
per 30 sec)** 
12.4 1.5 12.6 1.5 12.2 1.5 0.397 
Right/Left/Both 
Hands (pins per 
30 sec)** 
42.4 4.1 43.1 4.2 41.6 4.0 0.276 
Assembly (pieces 
per 60 sec)** 
28.9 3.9 29.8 3.9 27.9 3.6 0.091 
Right Hand 
Adjusted 
(seconds) 
23.3 6.0 24.0 7.1 22.4 4.4 0.752 
Left Hand 
Adjusted 
(seconds.) 
26.9 9.1 23.3 7.1 31.0 9.7 0.005 
Folate 
(nmol/L)** 
42.3 19.0 47.8 20.8 42.8 17.2 0.740 
B12 (pmol/L)** 354.9 224.4 429.3 268.9 267.4 111.4 0.017 
TCII (pmol/L)** 55.5 37.7 67.1 39.1 41.9 31.9 0.041 
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 The B12 containing supplement users had significantly better (p=0.005) left-
handed manual dexterity than those not taking B12 containing supplements.  In addition, 
participants who reported consuming B12 containing supplements had significantly 
higher serum B12 (429.3 ± 268.9, p=0.017) and TCII (67.1 ± 39.1, p=0.041) than those 
who did not report consuming B12 containing supplements (267.4 ± 111.4, 41.9 ± 31.9 
respectively). 
When comparing the participants who received their supplemental vitamin B12 
from multivitamin supplements and those who received their supplemental vitamin B12 
from stand alone B12 or B-complex vitamins, there was a significant difference in left 
hand adjusted manual dexterity (p=0.014, favoring stand alone supplement users), left 
hand fine dexterity (p=0.042, favoring multivitamin users), and average velocity, path 
length, and area effective (p=0.037, p=0.037, p=0.027 respectively; favoring stand-alone 
supplement users). 
Among those consuming B12 containing supplements, ten participants reported 
consuming their supplemented B12 within a combination multivitamin or powder.  
Eleven participants reported consuming their supplemental B12 as stand-alone B12 or B-
complex supplements.  The participants who reported taking stand-alone B12 or B-
complex supplements had significantly better balance outcomes scores for average 
velocity (p=0.037), path length (0.037), and area effective (0.027) than the participants 
who reported taking combined B12 supplements.  Stand-alone B12 supplement users also 
had significantly worse left hand Purdue Pegboard scores (p=0.042) and left-hand manual 
dexterity scores (p=0.014) than combined B12 supplement users.  Finally, there was no 
significant difference in serum B12, TCII, or folate concentrations between stand-alone 
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and combined B12 users.  Although not significant, the mean serum B12 of stand-alone 
vitamin B12 supplement users was slightly higher (446.4 ± 362.1 pmol/L) than that of the 
combined supplement users (412.2 ± 144.5 pmol/L). 
 According to Table 11 below, left hand adjusted manual dexterity was moderately 
correlated with serum B12 concentration (R = -0.351, p=0.031).  Figure 6 shows the 
relationship between non-transformed serum B12 and Functional Dexterity Left Hand 
Adjusted scores.  Figure 7 shows the relationship between B12 and Functional Dexterity 
Left Hand Adjusted scores using logarithmic transformations for both values to attain 
normal distribution.  The average Y and X axis velocities, as well as area 95, displayed 
moderate and weak correlations with serum B12 that were trending toward significance 
(R = 0.314, p=0.058; R = -0.286, p=0.086; R = -0.296, p=0.075 respectively).  The 
Purdue Pegboard assembly test scores were also moderately correlated (R = 0.317) with 
serum B12, with a p-value trending towards significance (p=0.052).  TCII was not 
significantly correlated with any outcome variables.  Controlling for serum folate 
concentrations did not alter the significance of any correlation.  Controlling for hand 
dominance strengthened the correlation between serum B12 and left-hand manual 
dexterity (p=0.029, R=-0.360).  In addition, controlling for hand dominance also revealed 
significance between serum B12 and Purdue Pegboard assembly scores (p=0.027, 
R=0.363). 
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Table 11. Correlations between biochemical values and outcome variables. 
  B12 TCII Folate B12 TCII 
Controlling for       Folate Folate 
  R p R p R p R p R p 
Vy Max (in/sec) 0.314 0.058 0.101 0.550 0.181 0.283 0.289 0.088 0.088 0.608 
Vx Max (in/sec) -0.216 0.207 -0.001 0.997 -0.055 0.751 -0.209 0.227 0.003 0.988 
V average (in/sec) -0.149 0.378 0.022 0.897 0.050 0.769 -0.163 0.343 0.018 0.917 
Path Length (in) -0.149 0.377 0.022 0.898 0.050 0.769 -0.163 0.343 0.018 0.918 
Area Effective (in2) -0.247 0.140 -0.082 0.629 -0.040 0.814 -0.245 0.151 -0.079 0.646 
Area 95 (in2) -0.296 0.075 -0.097 0.570 -0.081 0.635 -0.286 0.090 -0.091 0.599 
VT (Microns) 0.135 0.419 0.116 0.488 0.052 0.758 0.128 0.452 0.112 0.508 
Right Hand (pins per 30 sec)** 0.058 0.731 -0.216 0.193 0.084 0.615 0.044 0.798 -0.225 0.188 
Left Hand (pins per 30 sec)** 0.039 0.818 -0.174 0.297 0.076 0.648 0.019 0.910 -0.182 0.288 
Both Hands (pins per 30 sec)** 0.126 0.452 -0.172 0.301 0.295 0.072 0.073 0.672 -0.206 0.228 
Right/Left/Both Hands (pins per 
30 sec)** 
0.083 0.622 -0.213 0.199 0.169 0.310 0.050 0.771 -0.231 0.175 
Assembly (pieces per 60 sec)** 0.237 0.157 -0.132 0.437 0.322 0.052 0.188 0.273 -0.166 0.334 
Right Hand Adjusted (seconds) 0.143 0.404 0.203 0.235 -0.222 0.193 0.189 0.276 0.222 0.199 
Left Hand Adjusted (seconds) -0.351 0.031 -0.172 0.302 -0.226 0.173 -0.343 0.041 -0.163 0.341 
 
    66
 
Figure 6: Association between serum B12 and left-hand adjusted scores from the 
Functional Dexterity Test.   
 
 
 
Figure 7: Association between log(serum B12) and log(left hand adjusted score) from the 
Functional Dexterity Test.   
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 Finally, we explored the differences between two groups of participants clustered 
using the 50th percentile for serum vitamin B12: 303 pmol/L.  When comparing the low 
serum B12 and high serum B12 groups, the low B12 group required significantly more 
time to complete the left hand Functional Dexterity Test (p = 0.034).  In addition, the 
difference between the low and high B12 groups was trending toward significance for the 
Purdue Pegboard Assembly test and the area95 balance outcome variable (p=0.057, 
p=0.057).  However, when the area95 variable was transformed using square root, the 
difference between the low and the high B12 groups became significant (p=0.030). 
Intervention Data Analysis 
 Twenty-eight participants were qualified and randomly assigned for the 
intervention portion of this study (figure 8).  Four participants did not complete the initial 
visit.  Six participants dropped from the study during the intervention, the majority of 
whom dropped due to scheduling conflicts.  Ultimately, 18 subjects completed the 
intervention study: 8 in the placebo group and 10 in the vitamin B12 supplement group. 
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Figure 8. Participant recruitment and retention for the intervention portion of thus study. 
Demographic characteristics of the 18 participants enrolled in the intervention 
portion of the study are shown below in Tables 12 & 13.  The majority of participants 
were Caucasian females, eight being vegetarian and ten being vegan.  The average age of 
the intervention participants was 27 years.  The average BMI of participants was 22.3 
kg/m2, falling into the normal weight category.  The average supplement adherence for 
all subjects is 2 pills missed for both the intervention and placebo groups.  All 
participants in the intervention portion of this study were right-handed, so no adjustments 
for hand dominance were needed. 
Table 12: Demographics characteristics for Intervention and Control Participants 
Variable 
Number  (%)  
Total (n=18) 
Intervention 
(n=10) 
Placebo (n=8) 
 
Gender     
Male 4 (22.2) 2 (20.0) 2 (25.0)  
Female 14 (77.8) 8 (80.0) 6 (75.0)  
Ethnicity     
Native American 0 0 0  
African-American 0 0 0  
Caucasian 15 (83.3) 8 (80.0) 7 (87.5)  
Hispanic 1 (5.6) 1 (10.0) 0  
Asian 2 (11.1) 1 (10.0) 1 (12.5)  
Other 0 0 0  
Diet     
Vegan 10 (55.6) 7 (70.0) 3 (37.5)  
Lacto-Ovo 
Vegetarian 
8 (44.4) 3 (30.0) 5 (62.5)  
Diet Length     
3-5 years 8 (80.0) 6 (60.0) 2 (25.0)  
More than 5 years 10 (55.6) 4 (40.0) 6 (75.0)  
Activity     
Not active 0 0 0  
Somewhat active 8 (44.4) 3 (30.0) 5 (62.5)  
Active 5 (27.8) 5 (50.0) 0  
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Very Active 5 (27.8) 2 (20.0) 3 (37.5)  
Supplementation     
B12 Containing 
Supplements 
9 (50) 6 (60) 4 (50) 
 
  
 
 
Table 13.  Demographic Characteristics of the 18 subjects enrolled in the intervention 
portion of the study. 
 Total (n=18) INTV (n=10) Placebo (n=8) 
Variable Mean SD Mean SD Mean SD 
Age 27.1 5.6 26.0 5.4 28.50 5.8 
BMI 22.3 2.9 22.0 2.5 22.8 3.4 
Physical Activity 
(METs weekly) 
71.6 47.0 80.8 50.6 60.0 42.4 
Alcohol consumption 
(drinks per week) 
1.3 2.5 0.8 1.6 1.9 3.4 
 
Shapiro-Wilk normality tests of outcome variables revealed normal distribution 
for the following variables: some balance markers (y-axis maximum velocity, average 
velocity, path length), all Purdue Pegboard variables, all functional dexterity test 
variables, folate, and transcobalamin II.  The following variables were abnormally 
distributed: some balance markers (x-axis maximum velocity, area effective, 95% area), 
vibration threshold (in vibration units and microns), and vitamin B12. 
Table 14. Normality Testing of Major Outcome Variables in the Intervention 
Participants 
Outcome Variable Significance Transformation Significance 
Balance 
Vy Max 0.935   
Vx Max 0.010* Logarithm 0.455 
V average 0.059   
Path Length 0.059   
Area Effective 0.000* Logarithm 0.263 
Area 95 0.001* Logarithm 0.319 
Vibration 
Threshold 
VT (Vibration Units) 0.014* Logarithm 0.596 
VT (Microns) 0.000* Logarithm 0.596 
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Fine 
Dexterity  
Purdue 
Pegboard 
Right Hand 0.927   
Left Hand 0.938   
Both Hands 0.967   
Right/Left/Both Hands 0.839   
Assembly 0.926   
Manual 
Dexterity 
Functional 
Dexterity 
Test 
Right Hand Raw 0.415   
Right Hand Adjusted 0.083   
Left Hand Raw 0.444   
Left Hand Adjusted 0.123   
Biochemical 
Data 
Folate 0.421   
B12 0.000* Logarithm 0.136 
TCII 0.334   
 
Confounder analysis reveals physical activity to be a confounder for average 
velocity, path length, area effective, and area 95.  This analysis also revealed age to be a 
confounder for functional dexterity test right-hand adjusted scores.  Finally, TCII is 
confounded by diet type.  Due to measurement errors, subject 22’s balance data at time 2 
was removed from the analysis.  Subject 27s serum B12 level is an outlier, as it was more 
than three standard deviations away from the mean.
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Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Vy Max -2.54 0.830 -2.62 2.88 0.25 2.96 -2.95 0.86 -3.88 2.25 -0.94 2.38 0.556 0.025
Vx Max 2.99 1.58 2.54 3.09 -0.45 3.23 2.62 0.915 3.69 1.83 1.08 2.18 0.113 0.170
V average 0.832 0.215 0.862 0.667 -0.02 0.65 0.978 0.302 1.104 0.599 0.13 0.72 0.859 0.003
Path Length 49.92 12.92 15.90 10.73 -31.80 14.29 58.72 18.09 17.79 8.56 -40.9 18.66 0.209 0.118
Area Effective 1.47 2.041 0.202 0.172 -1.19 1.92 0.971 0.510 0.216 0.166 -0.70 0.60 0.568 0.026
Area 95 2.69 2.92 0.466 0.433 -2.09 2.75 2.46 1.54 0.552 0.376 -1.91 1.66 0.732 0.009
VT (Vibration 
Units) 0.864 0.424 0.786 0.234 -0.120 0.466 0.824 0.202 0.707 0.107 -0.12 0.184 0.751 0.007
VT (Microns) 0.453 0.507 0.333 0.173 -0.167 0.492 0.357 0.163 0.255 0.080 -0.1 0.150 0.640 0.015
Right Hand** 15.4 1.3 16.2 1.4 0.8 1.1 15.9 1.6 16.4 1.4 0.6 0.6 0.470 0.035
Left Hand** 14.9 1.0 15.0 1.4 0.1 0.7 14.3 2.1 14.9 2.2 0.7 0.6 0.081 0.189
Both Hands** 12.7 1.3 12.8 1.6 0.2 0.7 12.3 1.7 12.4 1.8 0.2 0.6 0.857 0.002
Right/Left/Both 
Hands** 42.9 3.4 44.0 4.3 1.1 1.7 42.5 4.9 43.7 5.2 1.6 1.0 0.832 0.003
Assembly** 29.3 3.0 30.8 3.9 1.5 2.5 28.4 5.7 29.6 2.8 2.0 3.7 0.837 0.003
p pη2Post Pre
Table 15: Time*Group Significance and Effect Size for Outcome Variables
ΔΔ
Intervention Placebo
Post
Balance
Vibration 
Threshold
Fine Dexterity  
Purdue 
Pegboard
Outcome Variable Pre
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Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Right Hand 
Raw 21.9 3.2 21.3 3.7 -0.1 3.1 22.1 6.8 21.0 4.0 -1.9 3.4 0.745 0.007
Right Hand 
Adjusted 21.9 3.2 23.5 7.6 2.4 5.9 23.4 8.6 23.5 7.1 -0.4 11.0 0.468 0.038
Left Hand Raw 22.8 5.5 21.3 3.8 -0.9 3.3 24.5 6.9 24.5 6.4 0.1 2.4 0.180 0.116
Left Hand 
Adjusted 26.2 6.7 22.4 5.3 -2.9 4.9 29.5 12.9 26.4 7.5 -3.4 8.2 0.807 0.004
Folate** 42.2 20.9 37.1 22.2 -5.0 14.4 52.2 22.8 37.9 15.2 -14.3 17.8 0.239 0.085
B12** 418.1 339.4 572.9 466.4 154.8 186.8 336.0 184.7 315.1 147.8 -20.6 137.9 0.042 0.234
TCII** 57.5 36.2 123.6 127.7 66.1 126.6 50.2 35.9 42.6 36.4 -7.8 65.4 0.155 0.122
Variable
Intervention Placebo
p pη2Pre Post Δ Pre Post Δ
Manual 
Dexterity 
Functional 
Dexterity Test
Biochemical 
Data
Table 15: Time*Group Significance and Effect Size for Outcome Variables
Outcome
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Δ Mean Δ SD Δ Mean Δ SD
Vy Max 0.025 2.96 -0.936 2.383 2.687 0.358
Vx Max -0.448 3.233 1.077 2.185 2.759 0.553
V average -0.025 0.653 0.0125 0.721 0.688 0.055
Path Length -31.78 14.29 -40.93 18.66 16.619 0.551
Area Effective -1.190 1.920 -0.699 0.597 1.422 0.345
Area 95 -2.09 2.75 -1.91 1.66 2.271 0.079
VT (Vibration Units) -0.120 0.466 -0.117 0.184 0.354 0.008
VT (Microns) -0.167 0.492 -0.109 0.140 0.362 0.160
Right Hand** 0.8 1.1 0.7 0.6 0.886 0.113
Left Hand** 0.1 0.7 0.7 0.6 0.652 0.920
Both Hands** 0.2 0.7 0.1 0.7 0.700 0.143
Right/Left/Both Hands** 1.1 1.7 1.2 1.4 1.557 0.064
Assembly** 1.5 2.5 1.2 4.1 3.396 0.088
Right Hand Raw -0.1 3.1 -1.1 3.8 3.468 0.288
Right Hand Adjusted 2.4 5.9 0.1 10.3 8.393 0.274
Left Hand Raw -0.9 3.3 0.0 2.2 2.804 0.321
Left Hand Adjusted -2.9 4.9 -3.1 7.7 6.447 0.036
Folate** -5.0 14.4 -14.3 17.8 16.190 0.574
B12** 154.8 186.8 -20.6 137.9 164.181 1.068
TCII** 66.1 126.6 -7.8 65.4 100.759 0.733
Outcome
Table 16: Change data for outcome variables and effect size for this change data reported as Cohen's D
Variable
Intervention Control
Pooled SD Cohen's D
Balance
Vibration Threshold
Fine Dexterity  Purdue 
Pegboard
Manual Dexterity Functional 
Dexterity Test
Biochemical Data
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Table 15 and Table 16 both display effect size calculations.  Table 15 contains 
effect size using partial eta squared, while table 16 contains effect size using Cohen’s D.  
Unless otherwise noted, all effective size mentioned hereafter is referring to partial eta 
squared.  With the exception of vitamin B12, there were no significant time*group 
differences for any outcome test variables (Table 15).  There was a significant 
time*group difference in serum vitamin B12 (p=0.039).  In the intervention group, the 
serum B12 increased significantly after 8 weeks (p=0.017 including the outlier, p=0.032 
excluding the outlier).  In the placebo group, the serum B12 did not change over time 
(p=0.609).  The mean change in B12 over time increased by 31% in the intervention 
group and decreased by 8% in the placebo group (graph 4).  Graphs 5 and 6 display the 
individual variation within the intervention and placebo groups.  The serum B12 outlier is 
marked by an (*).  When the time*group interaction is analyzed for serum B12 with the 
outlier removed, the significance is lost (p=0.061) and the effect size decreases to 0.214.  
Upon removal of the outlier, the change in mean serum B12 over time for the 
intervention group decreased to 109.8 pmol/L.  When analyzing time*group interactions 
only for participants whose baseline serum B12 concentration was less than 303 pmol/L 
(intervention n=5, Δ=101.3 pmol/L; placebo n=4, Δ=-20.1 pmol/L), the time*group 
interaction was not significant, but had a partial effect size of 0.387. 
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Figure 9:  Change in mean serum B12 over time by the intervention and placebo groups.   
 
 
Figure 10:  Changes in serum B12 over time for intervention group participants.  
*Indicates an outlier. 
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Figure 11:  Changes in serum B12 over time for placebo group participants. 
The mean change in TCII increased by 115% over time in the intervention group 
and decreased by 15% over time in the placebo group (figure 9).  TCII serum 
concentrations did not increase significantly in the intervention group over time (p=0.133 
including the outlier, p=0.128 excluding the outlier).   In addition, the TCII serum 
concentration did not change over time (p=0.746).   Graphs 8 and 9 display the individual 
variation within the intervention and placebo groups.  When the time*group interaction is 
analyzed for serum TCII with the serum B12 outlier participant removed, the effect size 
decreases to 0.101 and remains non-significant (p=0.213).  Upon removal of the outlier, 
the change in mean serum TCII over time for the intervention group decreased to 29.1 
pmol/L.  
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Figure 12:  Change in mean serum TCII over time for the intervention and placebo 
groups. 
 
 
 
Figure 13:  Changes in serum TCII over time for intervention group participants.   
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Figure 14:  Changes in serum TCII over time for placebo group participants. 
When the time*group interactions were analyzed for participants with a baseline 
serum B12 less than 303 pmol/L, the effect size for left hand adjusted increased to 0.281, 
however significance was not achieved (p=0.142).  In addition, when controlling for 
depletion at baseline (less than 303 pmol/L), there was a significant time*group 
interaction for the Vx max outcome variable (p=0.049, pη2 =0.250).  When only the 
subjects with serum B12 less than 303 pmol/L were analyzed, the time*group interaction 
for Vx max had an effect size of 0.242, but was not significant (p=0.179).  For this 
analysis, the intervention group consisted of 5 subjects and the placebo group consisted 
of 4 subjects.   
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CHAPTER 5 
DISCUSSION 
This is the first study to compare the relationship between the vitamin B12 status 
of vegetarians with manual dexterity, balance, and sensory perception measures.   
Currently, plasma vitamin B12 assessment cutoffs (148 pmol/L for total vitamin B12 
concentration and 35 pmol/L for TCII concentrations) are based on non-specific anemia 
parameters:  hemoglobin value, normal MCV, and normal reticulocyte response 15.  
Further, the basis for the vitamin B12 DRI does not include data regarding neurological 
symptoms, arguably the most damaging and severe symptoms of deficiency.  The focus 
on anemia parameters as indicators of B12 deficiency is likely due to the anemia that is 
typically the first clinically recognizable symptom in vitamin B12 deficiency.   However, 
neurological complications also occur with vitamin B12 deficiency and can, if untreated, 
lead to frank dementia and death.  These trials examined the relationship between plasma 
total vitamin B12 concentrations, TCII concentrations, and neurological measures.   
Cross-sectional 
The results of this study revealed a moderate correlation (R=-0.351, p=0.031) 
between serum B12 and left-hand manual dexterity scores on the functional dexterity test.  
No other correlations were noted between other outcome variables and serum B12 or 
TCII.  Furthermore, when comparing participants who reported regularly supplementing 
with vitamin B12 and those who did not report this, the supplementing group had 
significantly better serum B12 (p=0.017), TCII (p=0.041), and left-hand manual dexterity 
than the non-supplementing group (p=0.005).  Although the correlation between B12 and 
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left-hand manual dexterity was strengthened after controlling for hand dominance, there 
were only 2 two left-hand dominant subjects.  Thus, these results only have external 
validity in a right-hand dominant population.  Nonetheless, the relationship between 
vitamin B12 and left-hand manual dexterity appears to be consistent in this portion of the 
study. 
Although there were few significant correlations between biochemical results and 
outcome variables, there were several group differences of note in outcome variables. 
Most notably, the length of diet adherence appears to have an effect on dexterity but not 
vibration sensitivity.  Differences in neurological outcomes were compared between the 
short-term (3-5 years) and long-term (>5 years) diet adherence groups due to the liver’s 
ability to store vitamin B12 and sustain the body in times of dietary depletion up to 3-5 
years 20.  This is evidenced by a significant difference in four of the five Purdue Pegboard 
variables between the short-term vegetarians and vegans (3-5 years of diet adherence) 
and long-term vegetarians and vegans (>5 years of diet adherence).  In addition, there 
was also a difference between the long-term and short-term groups for the Functional 
Dexterity Test left hand adjusted score (p=0.042).  When comparing the short-term and 
the long-term diet adherence groups, the mean test completion time for the short-term 
diet group was nearly six seconds shorter than the long-term diet adherence group 
(p=0.042).  According to Sartorio et al., the 50th percentile reference norm for adjusted 
non-dominant (left in this study sample) hand is 23.2 seconds for males and 23.9 seconds 
for females between 20 and 49 years of age 91.  The average score for the high B12 group 
was 23.4 seconds, which is very similar to the 50th percentile reference norm for this age 
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range.  However, the average score for the low B12 group was 29.7 seconds, closer to the 
84th percentile reference norm (29.8 seconds for males, 32.6 seconds for females).  A 
difference of six seconds in a 24-second task is noteworthy, as this may indicate declines 
in skills such as handwriting and typing 55.  The short-term diet adherence group also had 
significantly better scores on the Purdue Pegboard left-hand dexterity test (p=0.003).  
Although the difference between the two groups (1.5 pins) does not appear as striking as 
that of the left hand Functional Dexterity Test, subtle decreases in fine dexterity may 
affect daily activities such as buttoning a shirt or texting.  Although the short-term diet 
adherence group had a higher mean serum B12 (390 pmol/L) than the long-term diet 
adherence group (331 pmol/L), there were no significant differences in serum B12 or 
TCII between the two diet length groups.  This suggests that these functional differences 
in fine dexterity are due to a different underlying factor not measured in this study.  For 
example, it is possible that a metabolite of the vitamin B12 metabolic cycle, such as 
homocysteine, is a mediator for the impact of vitamin B12 on nervous system function.  
One study found that children whose mothers had high maternal homocysteine 
concentrations at 26 weeks gestation had significantly lower (worse) dexterity scores than 
children whose mothers had normal plasma homocysteine at 26 weeks gestation 92.  
Although plasma homocysteine tends to be elevated in vegetarians and vegans 93, plasma 
homocysteine concentration is impacted by other nutrients such as folate and vitamin B6 
20. 
While the Purdue Pegboard likely requires proper functioning of sensory nerves 
and motor nerves, the vibration sensitivity testing likely requires only proper functioning 
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of sensory nerves (as there is no movement involved in sensing the vibration intensity).  
Thus the group difference in the dexterity variables, but not the vibration sensitivity, 
suggests possible motor nerve differences between the diet adherence groups.  Due to the 
cost and need for a physician, however, nerve conduction velocities were not measured in 
this study.  Thus, the difference between a motor and sensory nerves is merely 
speculative. 
 As nutrient interactions can often affect the bioavailability of a vitamin or 
mineral, it is important to examine the nutrient composition of supplements.  Yamada et 
al. found that compounds such as sugar, iron, and vitamin C promote the conversion of 
vitamin B12 to biologically inactive B12 analogues.  In addition, liquid supplements are 
also sensitive to storage time, light, and temperature, however solid supplements in this 
study were not as sensitive to environmental conditions as their liquid counterparts 94.  
However, due to the possibility of vitamin B12 degradation, group differences were 
examined between participants who obtained supplemental vitamin B12 from 
multivitamins and those who obtained vitamin B12 from B-complex or ‘stand-alone’ B12 
supplements.  Although there were several significant group differences, they were not 
consistent.  For example, the group who reported taking combined supplements had 
better scores for some balance markers (average velocity, path length, and area effective) 
and left-hand manual dexterity, but worse left-hand fine dexterity.  In addition, there was 
no significant difference between vitamin B12 and TCII between the two groups, 
although serum B12 for the combined supplement group (412 pmol/L) was lower than 
that of the B12/B12 complex group (446 pmol/L).  The validity of the statistical analysis 
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for this group comparison is diminished by low sample sizes for the combined 
supplement group (n=10) and the B12/B12 complex group (n=11).  These results suggest 
the possibility that a secondary nutrient (possibly found in combined supplements) may 
be the cause for the group difference in balance and dexterity markers, as serum B12 did 
not vary significant across groups.  However, more research with larger sample sizes 
examining the functional consequences of vitamin B12 supplemental source is needed to 
confirm this speculation. 
Group differences in outcome scores using a new cut-off point for defining 
deficiency based on the 50% percentile of serum B12 (303 pmol/L) for the 38 
participants were also examined.  In participants grouped by the 50th percentile for serum 
vitamin B12 concentrations (303 pmol/L), the high serum B12 group had significantly 
better left-hand manual dexterity scores (p=0.034) than the low serum B12 group (which 
contained no deficient individuals).  Thus left-hand dexterity appears to be directly 
related to vitamin B12 concentrations, as well as to the length of vegetarian or vegan diet 
adherence.  This research supports recent research that concludes that true vitamin B12 
deficiency cannot be ruled out in cases of serum concentrations between 156 and 450 
pmol/L 53.  This analysis also revealed a significant difference for area95 between the 
high and low serum B12 groups (p=0.030; data square root transformed to achieve 
normality).  This, combined with the moderate effect size of 0.170 for Vx max in the 
intervention portion of the study, is evidence for the need of further research on the 
effects of vitamin B12 nutriture on balance measures, perhaps in the elderly or deficient 
individuals.  However, one recent study which examined neurological outcomes after 
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supplementation in older adults also found no changes in functional neurological 
outcomes upon supplementation of vitamin B12 95.  As none of the subjects were 
deficient according to the current definition of vitamin B12 deficiency (<148 pmol/L), 
the negative consequences of low nutriture above deficiency provided also further 
evidence for the need to reexamine the vitamin B12 deficiency cut-offs. 
The strengthened relationship between vitamin B12 depletion and balance at 
lower serum B12 nutriture suggests that balance is the first neurological outcome affected 
by inadequate vitamin B12.  Similar results were observed in a recent study where 
investigators did not observe a pronounced change in the nerve conduction speed in the 
median nerve in the arm, but did document a change in the nerve conduction speed in the 
sural nerve on the leg.  Brito et al. suggested that this was possibly due to vitamin B12 
deficiency demyelination affecting larger afferent peripheral nerves 79, rather than the 
smaller branches located in the fingertips.  
Intervention  
 The results of the intervention portion of this study revealed no significant change 
in outcome variables over time between the intervention and placebo groups.  Although 
there were several large and moderate effect sizes, the change in these variables were not 
significant.  However, when controlling for B12 depletion (<303 pmol/L) at baseline, the 
intervention group’s Vx max scores improved significantly more than the placebo groups 
scores (p=0.049).  In addition, when examining the changes in neurological outcomes 
over time between the two groups, there was a large effect size (pη2 =0.242) related to the 
change in Vx max favoring the intervention group (p=0.179).  When analyzing this group 
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difference using Cohen’s D, the effect size is moderate (Cohen’s D = 0.553).  As the 
sample size was small for this analysis (n=9), it is again important to examine the effect 
size in addition to the p-value (p=0.113).  When examining only those participants whose 
serum B12 was less than 303 pmol/L at baseline, the effect size regarding the difference 
between the intervention and placebo groups over time was strengthened (pη2 =0.281).  
This again suggests that improvements in neurological function, particularly balance, are 
more profound for individuals who are in a state of depletion rather than B12 excess. 
Change in nervous system markers of the lower limbs, but not the upper limbs, is 
consistent with pervious literature.  Similar results were observed in a recent study where 
investigators did not observe a pronounced change in the nerve conduction speed in the 
median nerve in the arm, but did document a change in the nerve conduction speed in the 
sural nerve on the leg 79.  In addition, in cases of diabetic neuropathy, the feet are 
typically affected before neuropathy develops in upper extremeties 96. 
In addition to the lack of time*group interactions related to outcome variables, 
there is only one time*group interaction for biochemical markers which is lost after 
removing outliers from analysis.  While the intervention group’s serum B12 increased 
significantly more than the placebo group’s serum B12 concentrations over time 
(p=0.042, pη2=0.234, Δ=154.8 pmol/L), this significance disappeared when the outlier 
was removed (p=0.061, pη2=0.214, Δ=109.8 pmol/L).  With the outlier removed, 
however, the change in serum B12 (109.8 pmol/L) is trending towards significance.  
When removing the serum B12 outlier participant from TCII analysis, the change in 
serum TCII over time between groups remained not significant (p=0.213, pη2=0.101).  
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However, the TCII data point from the participant who had a very high serum B12 is not 
an outlier and should remain in the analysis. 
 The non-significant increase in serum B12 (with the outlier removed) and TCII 
after 8 weeks of 500mcg daily supplementation (208% of the RDA) of vitamin B12 is a 
surprising result.  However, when analyzing only those participants whose baseline 
serum B12 was below the 50th percentile (303 pmol/L), there was a strong effect size of 
0.387 (p=0.074) for daily supplementation.  However, in cases of small sample size such 
as this (5 in the intervention group and 4 in the placebo group), it is important to take 
both the significance and the effect size into consideration.  The large, although not 
significant, change in serum B12 in the intervention group (pη2=0.234) combined with 
the large increase in the effect size of the time*group interactions for participants whose 
baseline serum B12 was below the 50th percentile, suggests that vitamin B12 
supplementation may have a more pronounced effect on those individuals who are in a 
state of vitamin B12 depletion (<303 pmol/L serum concentration).  However, when 
using the Cohen’s D calculation, there is only a small effect size (Cohen’s D = 0.465) 
when supplementing vitamin B12 in the vitamin B12 depletion group. 
This lack of a significant increase in serum B12 (after outlier was removed) and 
TCII over time also suggests that 8 weeks of oral supplementation is not a long enough 
period to create significant change in plasma vitamin B12.  Eight weeks was selected for 
the trial length due to the typical resolution of hematological abnormalities within this 
time frame 8.  However, there is a lack of consistent information in the literature 
regarding the length of time for resolution of neurological symptoms.  In one study 
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examining the treatment times necessary to resolve vitamin B12 deficiency symptoms in 
more severe cases, investigators found that only 54% of patients responded to 13 months 
of treatment with vitamin B12 injections 97.  However, no studies have examined the 
supplementation to reverse early neurological symptoms.  As these subtle changes are 
difficult to recognize, healthcare providers typically see patients who are later in 
symptom progression.  For example, one study found that patients had been experiencing 
symptoms of vitamin B12 deficiency for an average of 10 months before being seen by a 
healthcare professional 97.  Thus, it is likely that improvements in neurological measures 
would require long-term supplementation, possibly greater than 13 months. 
Conclusion 
 We conclude that vitamin B12 appears to have more consistent relationships with 
neurological outcome variables than holo-transcobalamin II.  In addition, there is a 
relationship between serum B12 and left-hand dexterity (in a population of right-hand 
dominant individuals), as well as a relationship between serum vitamin B12 and x-axis 
velocity in subjects whose serum vitamin B12 concentration is less than 303 pmol/L.  
More research is necessary to examine the relationship between vitamin B12 serum 
concentration and vitamin B12 supplementation on neurological outcomes, particularly 
balance and left-hand dexterity, in a large sample of subjects with baseline serum 
concentrations less than 303 pmol/L.  Although this study supports the notion that there 
are slight functional declines in balance in states of B12 depletion, the sample size for 
this study is small.  The functional consequences of vitamin B12 depletion (defined here 
as less than 303 pmol/L) need to be examined in a large-scale study to further elucidate 
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the clinical relevance of vitamin B12 depletion.  Finally, further research needs to be 
conducted as to the efficacy of oral supplementation in individuals who have serum B12 
concentrations in the low range of adequacy. 
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Force Plate – Balance 
 
1. Force Plate Set Up 
a. Make sure 30° tape is on force plate 
b. Set up force plate and laptop and connect to power source using the extension 
cord and power strip 
c. Ensure the force plate is connected to COM4 on the laptop 
d. Open Balance Clinic 
e. Ensure COM4 is selected in the “setup” section of BC 
f. Calibrate the force plate using the “digital XXXX .cal” file 
g. Select the B12CS protocol  
2. Posturography Analysis 
a. Click “select subject” and “add new” to enter each subject’s information 
b. Enter their subject number as the first name and the date (DD.MM.YY) as the 
last name 
c. Enter the subject’s height and weight as measured at the anthropometrics 
station 
d. Click “OK” 
e. Make sure that subject is selected, click “OK” 
f. Zero the platform 
g. Ask the subject to remove their shoes and socks 
h. Ask the subject to stand on the platform with their feet along the outside edge 
of the blue tape 
i. Ask subject to stand as still as possible with their arms at their side and 
stare at the designated marker on the wall straight ahead of them (i.e. 
no talking, no moving their head) 
ii. Redo the test if they move their feet 
i. Begin 10 second timer 
j. Once 10 sec is finished, click “Acquire” on BC 
i. BC will run the test for 60 seconds and will notify you when the test is 
complete (click “OK”) 
k. When the test is complete, ask the participant to step off of the force plate 
l. Click “Save Data” 
m. Sanitize the platform while the participant collects their belongings 
n. Export the data immediately to Google Doc 
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APPENDIX C 
VIBRATRON II PARTICIPANT SHEET 
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Physitemp Vibratron II – Vibration Sensitivity tester   Subject #: 
 
1. Ensure that module A is connected to socket A and module B is connected to socket 
B.  Make sure dampening pads are under each module. 
2. Turn on the machine and turn the operating range to ‘high resolution’. 
3. Adjust the output to the highest level (7.0-7.2). 
4. Allow participants to feel vibration.  Provide instructions for the test while 
demonstrating. 
a. “Please press your finger against each rod in sequence for approximately one 
second.  During each trial you will be allowed to touch the rods only once.  
Only one of the rods will be vibrating and you must decide whether it’s A or 
B.  The task will become increasingly more difficult and I understand that you 
will be guessing on many of the trials.” 
b. When I say “OK”, you will sequentially touch the top of each rod with the 
index finger on your dominant hand for one second each.  After doing so, you 
will tell me which module you believe is vibrating. 
c. The ideal force to touch the rod is just enough to blanch (make yellow) your 
fingernail (or surrounding skin if their nail is painted). 
d. Try to be as consistent as possible with the pressure that you use to touch each 
module. 
5. Make sure the subject cannot see the screen or switch labels. 
6. Begin a trial run where you flip the real switch and the dummy switch a few times.  If 
the participant correctly identifies the vibrating rod 100% of the time, then begin on 
the highest level of high resolution.  If the participant incorrectly identifies the 
vibrating module, the switch to low resolution and begin at 10.0, then 15.0, and so on. 
7. Begin the trial. Switch between A & B randomly.  If you do not switch modules, flip 
the dummy switch. 
8. After a correct identification, decrease the vibration units by 0.5. 
9. If the subject makes an error, that voltage setting should be repeated 3 times. 
10. If the vibrating module is correctly identified twice, then raise the units 0.5 and 
continue the trial. 
11. If two errors are made at the same voltage consecutively, a third attempt is 
unnecessary.   
12. All levels below 0.7 should be repeated twice. 
13. Complete the test when five errors are made. 
 
Vibration 
Units 
Correct Incorrect 
Vibration 
Units 
Correct Incorrect 
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1. What are the vibration settings of the five errors? 
 
 
 
    
 
2. What are the vibration settings of the five lowest correct scores? 
 
 
 
    
 
3. Cross out the highest and lowest values of these ten scores. 
 
4. Calculate the average of the remaining 8 scores.   This is the vibration threshold (in 
vibration units). 
 
 
 
  
5. Convert the vibration threshold from vibration units to microns using the formula 
below. 
 
A = (0.5)X2 
A = peak to peak amplitude in microns 
X = reading on digital display 
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APPENDIX D 
PURDUE PEGBOARD PARTICIPANT SHEET 
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Purdue Pegboard        Subject #: 
 
 Trial 1 Trial 2  Trial 3 Average 
Right Hand (30s)     
Left Hand (30s)     
Both Hands (30s)     
Right + Left + Both     
Assembly (60s)     
 
Setup 
1. Separate the pins equally, half in the far left cup and half in the far right cup.  Right 
hand gets a pin from the right.  Left hand take a pin from the left.  
1. RH DOMINANT: Place the washers in the cup that is right of the center of the board.  
Place the sleeves in the cup left of center. 
2. LH DOMINANT: Place the washers in the cup that is right of the center of the board.  
Place the sleeves in the cup left of the center. 
 
Pin Tests 
2. DOMINANT HAND 1st: Take one pin form the far right cup, insert it into the right 
top hole.  Keep inserting pins for 30 seconds.  Don’t pick up any dropped pins. 
3. NON-DOMINANT HAND 2nd: Take one pin with far left cup, insert it into the top 
left hold.  Keep inserting pins for 30 seconds.  Don’t pick up any dropped pins. 
4. BOTH HANDS 3rd: Pins must be placed simultaneously.  The pairs of pins are scored 
for the both hands test, not the individual pins.  (Ex: 8 pins would get a score of 4, as 
4 pairs will be present.) 
 
Assembly 
1. For RH dominant: Take a pin form the far right cup and insert it into the hole at the 
top.  Grab a washer with your left and drop the washer onto the pin.  Grab a collar 
with your right hand and place it onto the pin with the washer.  Grab another washer 
with your left hand and drop it onto the pin to complete the assembly.  Keep doing for 
60 seconds. 
2. For LH dominant: Repeat the same process but with the hands switched (washer in 
the middle-left and sleeves in the middle-right cups).   
3. Scoring:  Count all of the assembled parts to provide a score for the right hand.  (Four 
points for each completed assembly.  Partials count 1 point per piece.) 
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APPENDIX E 
FUNCTIONAL DEXTERITY TEST PARTICIPANT SHEET 
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Functional Dexterity Test       Subject #: 
 
1. Place the board 10 cm from the edge of the table. 
2. Ensure participant is comfortable. 
3. Record hand dominance of participant. 
4. Provide instructions for the test. 
a. Please start with your dominant hand. Start by turning the peg at the top 
opposite corner, turn all the pegs over as quickly as possible, turning over one 
row of pegs, then reversing the order in the next row, in a zigzag fashion. 
b. Do not turn your hand up to face the ceiling (supinate) or touch the board for 
help in turning the peg; each of these motions carries a penalty of 5 seconds. If 
you drop a peg, time is stopped, and a 10-second penalty is added. You then 
need to retrieve the peg and put it in the pegboard in the unturned position. 
Then continue to turn the pegs with the peg that you just put back. The clock 
starts where it was stopped, and the time is continued. 
5. Investigator demonstrates by turning over 4 pegs. 
6. Participants are allowed one practice round where they turn over all the pegs on the 
board once. 
7. Begin test.  Make sure to pause the time if the participant drops a peg.  Have them 
insert the peg back into the board in the unturned position.  Start the clock again when 
the participant resumes the test. 
 
 
Raw Score 
 
 
 
Supination 
 
  
x 5 seconds = 
 
 
Touching the board for 
help 
 
  
x 5 seconds = 
 
 
Dropped peg 
 
  
x 10 seconds = 
 
 
Adjusted Score 
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Vitamin B12/Folate Assay
Shake Binder
BRING ALL REAGENTS TO ROOM TEMP vigorously!
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7 Step 8  Step 9-11
Add Add 
Tube Add Standard/ Add Extract Add Blank Binder
Name Tube # QC or sample Tracer Reagent Reagent
Total Counts 1,2  - 200 µl  -  -  - 
NSB 3,4 200 μl  STD A (0 pmol/L) 200 µl 100 µl 1000 µl  - 
Ref (BO) 5,6 200 μl  STD A (0 pmol/L) 200 µl 100 µl 1000 µl
Std tube B 7,8 200 µl of 74 pmol/L 200 µl 100 µl 1000 µl
Std tube C 9,10 200 µl of 148 pmol/L 200 µl 100 µl 1000 µl
Std tube D 11,12 200 µl of 296 pmol/L 200 µl 100 µl 1000 µl
Std tube E 13,14 200 µl of 740 pmol/L 200 µl 100 µl 1000 µl
Std tube F 15,16 200 µl of 1480 pmol/L 200 µl 100 µl 1000 µl
Control low 17,18 200 µl of QC 1 200 µl 100 µl 1000 µl
Control med 19,20 200 µl of QC 2 200 µl 100 µl 1000 µl
Control high 21,22 200 µl of QC 3 200 µl 100 µl 1000 µl
sample 23,--- 200 µl of unknown 200 µl 100 µl 1000 µl
Transcobalamin II
While stirring, combine 100ul of slurry with 500ul of serum. Allow to sit for 10 minutes. Spin at 5000 x g for 10 minutes.  
Measure the supernatant for B12 levels.
TCII is determined by subtracting the precipitated  B12 from the non precipitated B12. 
Set-up
Mix 3 gms of Silica with 20mls of distilled water. Place on a stir plate and stir thoroughly.  Check edges of beaker for silica clumping - even with a stirbar in 
place. Store at 4 C if not used.
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